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      The budding yeast Candida glabrata (an opportunistic pathogen) has 
emerged as a major health concern, particularly in immunocompromised 
patients. A key virulence factor Epa1, is the founding member of the 
Epithelial Adhesin gene family. Structural characterization of the 
functional N-terminal lectin-binding domain of Epa1 is critical in 
identifying cognate receptor ligands on host cells. We employed glycan 
microarray analysis and pursued crystallographic analysis as our first 
approach. Since C. glabrata has lost its de novo NAD+ biosynthetic 
pathway, limitation for nicotinic acid (NA) or related vitamins in the 
media leads to NAD+ depletion in the cell and virulence effects. The 
known NAD+ dependent regulators Hst1 or Sir2 do not mediate the 
virulence effects of NAD+ limitation.  
 
      We previously employed microarrays to analyze the transcriptional 
response to NAD+ limitation. Among the several hundred genes induced 
by NA limitation are large sets of strongly up regulated genes that are 
orthologues of S. cerevisiae genes regulated by the transcription factors 
Bas1 and Bas2. In S. cerevisiae, BAS1 and BAS2 regulate several 
interconnected metabolic pathways, including histidine, purine 
biosynthesis, tetrahydrofolate metabolism, and phosphate utilization. We 
 iii 
have analyzed the transcriptional response of the Bas1 and Bas2 
regulons in conjunction with the Gcn4 regulon in C. glabrata in response 
to NAD+ limitation. We show that genes in the purine biosynthetic 
pathway are strongly up regulated by NAD+ limitation and that this 
requires Bas1 and Gcn4. We also show that mutants lacking BAS1 or 
both BAS1 and GCN4 are strongly compromised in virulence consistent 
with a role during infection, and potentially in mediating the hyper 
virulence associated with NAD+ limitation. Furthermore, an analysis of 
the purine biosynthetic pathway suggest that the effect of NAD+ 
limitation on transcription of purine biosynthesis genes may be due to 
decreased activity of IMP Dehydrogenase (IMPDH) which catalyzes the 
conversion of inosinate (IMP) to xanthylate (XMP). We present 
preliminary and compelling results that reveal NAD+ limitation leads to 
depletion of guanine nucleotides and to an overall imbalance of the 
nucleotide pools, which has wide-ranging repercussions. Inhibition of 
IMPDH in C. glabrata mimics some aspects of NAD+ limitation, including 
the increase of virulence.  
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Chapter 1      Background 
      There are approximately 1.5 million different fungal species identified 
but only about 300 of those are known to cause illness in people. 
Candidiasis is caused by about 20 different Candida spp. which are the 
most fungal pathogens causing bloodstream infections with mortality 
rates of up to 60%.1 While C. albicans is the most frequent pathogen, 
non-albicans Candida species are also important, particularly C. 
glabrata, which is the second most common Candida species causing 
bloodstream infections. This emerging yeast pathogen is characterized by 
unique features that warrant considerable attention to manage its 
diagnosis and treatment. In the general public C. glabrata exists as a 
commensal organism and is detected in about 20-30% of individuals. It 
is associated with increased morbidity and mortality in 
immunocompromised patients, including those with AIDS, in cancer 
patients and in organ transplant patients receiving chemotherapy or 
immunosuppressive drugs.2 As a causative agent of candidiasis C. 
glabrata exerts its biggest impact on the elderly population and those 
passing through hospital ICUs. Age and exposure to antibiotics especially 
azole type drugs are key indicators for C. glabrata infection. The resulting 
complicated nosocomial infections or UTIs are a consequence of some of 
the unique features that sets apart this pathogen. It possesses an 
inherent resistance to azole class anti-fungals. Other virulence attributes 
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include a family of adhesin genes (Epithelial Adhesin or EPA genes) that 
allow for colonization of epithelial and endothelial cells.  
 
      Our work builds on the efforts of previous and current lab members 
that showed how this EPA family is transcriptionally 
regulated/repressed. Of particular interest is the role of NAD+ as a 
regulator of virulence. The NAD+ status of C. glabrata cells is a key 
determinant of disease progression. C. glabrata is an NAD+ auxotroph, 
and cells that are starved for NAD+ overexpress the EPA family adhesin 
genes, and are hyper virulent. NAD+ is critical for signal transduction and 
a number of metabolic pathways; it is recycled during redox reactions 
and it is consumed when it functions as an enzymatic co-factor. These 
subtle features are clinically important since they appear to provide C. 
glabrata a mechanism toward pathogenicity and are clearly demonstrated 
by its capacity to adhere to abiotic surfaces, notably through indwelling 
catheters with high incidence rates in hospital ICUs. One of our studies 
looked to uncover the downstream sensors or pathways that are 
impacted by an NAD+ limiting environment which resultantly led to the 
possibility that GMP or nucleotide imbalances are the true drivers of C. 
glabrata virulence.   
 
      Incredibly, since the 1980’s, no new classes of antifungals have made 
it to the clinical stage or beyond with the exception of echinocandin and 
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its various derivatives. Understandably, the shared eukaryotic nature of 
fungal and mammalian cells demands the creation of antifungal agents 
with a high degree of selectivity and specificity for fungal cells. The cell 
wall is a unique organelle that has proven to be an effective target for 
developing antibiotics against bacterial infections. A similar strategy has 
been applied against yeast infections where the major targets are chitin, 
mannan and (1,3) β-D glucan synthesis. These polysaccharide polymers 
are absent from mammalian cells; they therefore represent attractive 
sites of intervention for drug development. Echinocandin lipopeptides are 
fungicidal with low toxicity and with very low incidence of resistance in 
C. glabrata reported. The drawback with this class of medicines is their 
poor oral bioavailability hence they are usually only administered 
intravenously. One current drug trying to address this clinical need is 
the semi-synthetic enfumafungin derivative MK-3118, originally 
identified by Merck now under clinical trials by Scynexis known as SCY-
078, a novel oral and intravenous drug that has shown to be effective 
against invasive fungal infections, at least in animal studies.3  
Our research on the EPA family of adhesins, and the initial binding step 
of infection could possibly lead to the development of a new class of 
antifungals. In addition, the studies surrounding this family of adhesins 
culminated in the identification of novel glycan ligands recognized by Epa 
family adhesins. The results may help identify potential new cell types 
targeted during infection.   
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      The following work focused on the general mechanisms of C. glabrata 
virulence with the intent of furthering our understanding of specific 
components of the pathogen’s cell wall as well as the identification of 
regulatory mechanisms governing the response of C. glabrata to NAD+ 
limitation. Increased advances in our knowledge may ultimately lead to 
effective new agents against C. glabrata or even other invasive Candida 




Chapter 2      EPA Lectins and Glycan Ligands 
2.1 Introduction 
      Amongst clinically relevant Candida species, C. glabrata is the second 
most commonly isolated species after C. albicans.4 Candida glabrata is an 
increasingly relevant pathogenic yeast accounting for both mucosal and 
blood stream infections in humans. The initial step in infection is 
thought to be adherence of the organism to target human tissues. In the 
past several years adhesins encoded by the EPA gene family have been 
shown to be the key mediators of the host-pathogen interaction. The 
founding member EPA1 (Epithelial Adhesin -1) was discovered to bind 
avidly to human epithelial cells in culture.5 Early work also suggested 
that Epa1 was a Ca2+ dependent lectin similar to the Saccharomyces 
cerevisiae Flo1, a surface protein known to be involved in protein – 
glycan recognition during yeast flocculation.6 Dissection of the Epa1 
functional domains defined characteristic signaling sequences that direct 
the protein to traffic and localize to the cell wall specifically. Further 
analysis through sequence homology allowed the identification of 
additional EPA gene family members.7–9 Over the past several years, our 
lab (Cormack-JHU) has focused on understanding the adhesion 
mechanisms and characteristics of the EPA family of cell wall localized 
adhesins discovered in C. glabrata, specifically for the BG2-strain.  
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      Most of the known fungal adhesins are GPI - anchored cell wall 
proteins. They possess a very well characterized modular architecture 
composed of an N-terminal carbohydrate ligand binding domain followed 
by a central highly repetitive and heavily O-glycosylated Ser/Thr rich 
region and a terminal hydrophobic sequence denoting the GPI anchor 
site.10 The functional region, located at the N-terminus, in Epa proteins 
and the Flo family homolog in S. cerevisiae has recently been identified 
as the “PA-14 domain”.11 This lectin domain was originally identified by 
homology to the 14kDa fragment of the Protective Antigen toxin 
component of Bacillus anthracis. A PSI-BLAST search analysis revealed 
the presence of a ~150 amino acid sequence as a new β-barrel domain 
that utilizes Ca2+ ions and whose presence has been uncovered in a 
variety of bacterial and eukaryotic glycosidases, glycosyl transferases, 
amidases, proteases, bacterial toxins, proteins involved in cell adhesion 
and in human polycystic kidney and hepatic diseases.11 The phylogenetic 
distribution of this motif encompasses a variety of bacterial and 
eukaryotic species but does not include Archae. This new domain was 
also found present in the pro-peptide fragment (PA20); a component of the 
anthrax toxin whose structure has been published.12 Although related, 
the critical loops for binding carbohydrates are of different length in the 
Epa adhesins and presumably impart unique binding selectivity.   
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      In Saccharomyces cerevisiae, gene silencing at the telomere is 
initiated by recruitment of the Sir complex (Sir2, Sir3, and Sir4) to 
telomeric repeats, followed by spreading into the adjacent subtelomeric 
region. The spread of silencing is dependent on the function of the sirtuin 
Sir2, a NAD+ -dependent histone deacetylase (HDAC). The same 
mechanism is found in C. glabrata. Sir2 becomes inactive in the absence 
of NAD+. Since C. glabrata is an NAD+ auxotroph, Sir2 and the related 
sirtuin Hst1 become inactive in environments limiting for vitamin B3 
(Nicotinic acid, nicotinamide, nicotinamide riboside). Under low NAD+ 
conditions (the subject of study for chapter II of this thesis) the Hst1 and 
Sir2 proteins become inactive, consequently gene silencing along the 
region is relieved. The EPA genes are encoded largely in sub-telomeric 
clusters, subject to Sir2-dependent transcriptional silencing and are 
subject to a novel form of pathogenic gene regulation whereby 
transcriptionally-silenced EPA genes are de-repressed during infection in 
host environments limiting for vitamin precursors of NAD+.9–16 In our 
particular lab strain BG2, C. glabrata encodes 25 EPA genes, 22 of which 
are encoded in sub-telomeric regions of the genome.17,18 Three genes in 
particular EPA1, EPA6 and EPA7 have been carefully studied and at least 
for EPA6 and EPA7 it has been shown that their expression during a 
murine model of urinary tract infection (UTI) is likely due to derepression 




      Interestingly, the three family members (Epa1, Epa6, Epa7) share  
>90% identity at the protein level, yet an analysis of their sugar binding 
specificities revealed a varied carbohydrate binding repertoire.19 Glycan 
microarray analysis has been used to determine the sugar binding range 
of Epa1, Epa6 and Epa7 using both purified proteins and whole S. 
cerevisiae cells. The essential results indicated that all three proteins 
bind to a terminal galactose residue with notable differences in the 
binding selections between Epa6 and Epa7 which share the highest 
sequence (protein) homology in the set.19 Moreover, Epa1 and Epa7 
prefer terminal disaccharides with a β-type linkage while Epa6 shows no 
preference for either linkage class (α or β).19 The binding differences 
between Epa6 and Epa7 have been ascribed to one or two amino acid 
changes within a small stretch of 5 residues. These results are striking 
and help explain the binding capacity difference for endothelial cells 
between these two lectins. Our current studies will support and/or 
emphasize earlier findings while extending the results to include a new 
set of EPAs namely, Epa12, Epa23 and Epa25. This ongoing study thus 
far is in keeping with previous overall results for Epa1, Epa6 and Epa7 
and presents compelling results for the new set of Epa proteins that 
show a predilection for more exotic glycan types such as sulfated or 
sialylated glycans.    
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      Many reasons necessitate a physical understanding at the structural 
level of Epa proteins that could reveal glycan specificity as well as help 
clarify the apparent overlapping and redundant functions of the Epa 
family of proteins. Structural characterization of the functional N-
terminal lectin-binding domain is critical in identifying cognate receptor 
ligands on host cells. 
 
      The importance of this family of adhesins as one of the main 
virulence factors for C. glabrata has been firmly established.18,20 The 
continued rise of C. glabrata infections and the emergence of other non-
albicans pathogenic species (NAC) prompts a rigorous study of the basic 
infectious strategies that could yield important information for 
prophylaxis protocols as well as new treatment regiments against 
mycotic infections.   
  
      The following studies were undertaken to try and determine the 
structural basis of Epa-mediated binding to host glycoconjugates and to 
establish a more comprehensive inventory of the full complement of EPA 
– glycan determinants. By way of structure analysis of the lectin domain 
of one of the Epa proteins and usage of glycan-microarray (glycochips) 
screening, we hoped to expand our understanding of the adherence step 




2.2.1 EPA 1 Sequence Analysis and Expression in E. coli 
      Factors affecting protein expression have been intensely studied to 
improve on heterologous recombinant protein expression.21 One of the 
important determining factors is the influence on translational efficiency 
of specific amino acids at the +2 position.22 To this end the Epa1 NT 
sequence region was put through the secondary structure prediction 
program - PredictProtein (PP; https://www.predictprotein.org Figure 2.1). 
Those results along with being guided by the recently described 
homologous region PA-14 domain and the known crystal structure of 
anthrax toxin allowed us to narrow down the size of our starting 
functional Epa N-terminal domain. This initial analysis aided in the 
production of a panel of expression constructs that ranged in size 
between 17 kDa and 35 kDa and in lengths of 150-320 amino acids as 
detailed in Table 2. A general N-end rule for predicting enhanced protein 
expression is the incorporation of Ala, Ser or Leu after the start Met 
residue whenever possible.23 The prediction program depicts a heavily 
unordered loop structured domain (L=67%) along with several β-sheets 
(E=33%) shown in Figure 2.1. The above considerations are certainly 
important but were rendered moot, once we decided to express these 
fragments as N-terminal fusions to His-Sumo1.  
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      The cloning schematic for Epa1-NT protein fragments is depicted in 
Figure 2.2 and further described in the Materials and Methods section. 
Sumo-1 has been well characterized and established in aiding in the 
solubility of a large number of recombinantly expressed proteins 
ultimately used for structural studies. Coomassie stained SDS-PAGE gels 
confirm the heterologous expression of our set of 14 fragments as His-
Sumo fusion proteins. The results from small Ni2+-NTA resin batch 
purification experiments shown in Figure 2.3 indicate an abundance of 
presumed degradation products. Fractions corresponding to elutions and 
resin are shown in panels A and B. Although there is substantial 
expression of practically all protein fragments there is marked protein 
instability as indicated by the large quantities of degradation products 
and/or aggregated protein near the lower molecular weight range of the 
gels (20-25 kDa). Nonetheless, PAGE migration analyses as evidenced on 
panels C, D and E from samples taken before and after IPTG induction 
do show the expected variations in protein sizes reflecting all the different 
constructs that were tested. Even so, the elutions samples show 
apparently unstable and improperly folded protein products.  
  
      There are several possibilities that could account for the 
disappointing behavior of all of the constructs. The His-sumo fusion tag 
could itself be interfering with the dynamics of the initial folding process. 
Many instances exist in the literature demonstrate that proteins do 
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benefit from a change in the placement of the affinity tag so a C-terminal 
tag rather than an N-terminal position could allow for better folding 
outcomes. In an attempt to improve protein solubility and stability we 
tested a number of parameters: salt, pH, reducing capacity and detergent 
solubility (Figure 2.4). The different buffer formulations were introduced, 
as crude cell lysates were prepared. Epa1 (version 1.2) overexpressed in 
bacterial cell pellets were subjected to various experimental buffers and 
carried through to the purification step in Imidazole elutions, yet none of 
the 11 different conditions tested from Table 2.2 did much to prevent 
protein instability.  
 
      Apart from the physical parameters that were addressed we 
considered more importantly the inherent attributes associated with the 
EPA family of lectins. Of real consequence are the facts that this N-
terminal domain is i) rich in Cysteine residues, with 5 predicted S=S 
bonds and ii) it possesses predicted post-translational N-glycosylation 
modification sites along residues (N140 and N333). Several potential N-
myristoylation sites were also predicted but likely do not affect 
expression. Given these features, it seems likely that the problem with 
protein stability has more to do with implementing the appropriate 
expression system rather than the conditions during the purification 
process. Consequently, we decided that a eukaryotic approach might be 
more accommodating for the particular characteristics of these lectin 
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proteins. Although currently there are new bacterial systems that are 
suited to expression of glycosylated and disulfide bond rich-proteins we 
opted to express the Epa domains in a eukaryotic heterologous 
expression system.  
2.2.2 Expression of Epa 1 in mammalian cells 
      The DNA fragments encoding Epa1 were transferred from our 
bacterial expression plasmids and subcloned into a mammalian 
expression system for production of secreted proteins in adherent HEK 
293 (GNTI-) cells. The cloning and purification protocols are detailed in 
the Materials and Methods section. Twenty construct fragments were 
created for metal chelation purification.21 Small batch experiments using 
6-well plates yielded mostly soluble, non-degraded proteins as shown in 
Coomassie stained PAGE gels (Figure 2.5). We cannot make any 
definitive conclusions with regards to the influence the various C-
terminal positions had on the stability of the panel of constructs. An 
overview of panel A - the elution fractions, suggests there could be an 
ideal fragment length imparting a stability influence that is exerted by 
different C-terminal positions, at least for the A30 group of constructs. 
Interestingly, we see that there is a complete loss of protein expression as 
the fragment becomes progressively more truncated from the N-terminus. 
Inspection of the primary sequence and our original secondary structure 
analysis shows that there exists a Cyc50 that is predicted to be part of a 
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disulfide bridge. Notably, the two sets of fragments where expression was 
successful started at A30 and L38. The next group, initiating at S62 failed 
to express and shows that Cys50 is critical for the overall architecture of 
this lectin domain. In fact, the solved structure has borne out the fact 
that Cys50 along with Cys179 help tether the N-terminal end to a loop 
between β6 and β7 rendering the desired compact shape for the 
protein.24 This Cys50 is also preserved in the distantly related Flo5 
protein from S. cerevisiae, where the PA14 domain has also been 
identified - suggesting a critical role for this residue. The lower panel B 
shows that there still remains a good percentage (~30-40%) of aggregated 
protein bound to the Ni2+ resin as well as some unknown non-specific 
Ni2+ binding protein. 
 
      In an effort to arrive at a more stable and well-expressed protein, a 
limited proteolysis experiment was conducted. Construct Epa 1.5 was 
subjected to several different concentrations of Proteinase K and 
visualized on a PAGE gel after Coomassie staining (Figure 2.6 insert). 
After overdigestion the sample was further processed for mass 
spectrometry analysis (Figure 2.6). These analyses helped identify an 
extremely stable core domain bounded by Ser40 and Ile283. Once this 
core domain was uncovered, new sets of constructs were sub-cloned 
using the corresponding residues for Epa 6 and Epa 7, as listed in Table 
2.4. Small-scale expression tests were confirmed by Western analysis 
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using an N-terminal specific antibody (lab-stock #3638) as displayed in 
Figure 2.7. Epa-NT mammalian expression is known to be low yielding 
showing only faint banding in Coomassie stained gels that are poorly 
visible in the Figure 2.7 image. Of note is the observation that although 
Epa1, Epa6 and Epa7 are of the same 1º sequence length there is a clear 
marked difference in the migration pattern displayed on the Western. 
GNTI- cells are deficient only for complex glycosylation structures but 
remain competent for simple mannose modifications. A reasonable 
assessment is that there are glycosylation differences between these 
genes although they share over 90% homology at the amino acid level. 
The functional consequences of these features remain to be fully 
delineated and explored.  
2.2.3 Purification of Mammalian Expressed Epa1p 
      A two-step purification scheme was developed for the Epa1. As 
detailed in the methods section, Epa1 was harvested as a secreted 
protein from HEK-293 (GNTI-) cells and passed over a Ni2+ IMAC column, 
followed by Ulp1 enzymatic treatment overnight for His-Sumo1 fusion 
removal. The collected protein (FT; flow-thru) was subsequently purified 
over a Lactose-sepharose column yielding a highly purified Epa1 species 
fraction (Figure 2.8 – Coomassie stained insert). Samples collected 
throughout each of the two purification steps were collected for analysis 
on SDS-PAGE. The Coomassie stained gel shows practically no or 
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minimal protein being captured by the resin in an aggregated manner. A 
portion of this material was then analyzed by HPLC using an S75 
diagnostic gel filtration column (Figure 2.8). The single peak UV trace 
offers a good indication that the protein is of a single mono-disperse 
species. Additional information about the general behavior of the protein 
can be inferred by the lack of detectable protein in the void volume; the 
latter is a sign of the presence of misfolded or aggregated proteins.     
 
      Marginally better protein yields from Epa7p prompted an initial full-
scale production for protein crystallization experiments. As detailed in 
the mammalian expression methods – once Epa7 was purified and 
concentrated (6 mg/ml), the protein was screened for crystallization 
conditions utilizing the Mosquito LCP robot on 96-well plates. Several 
commercial screens were attempted such as Index- (Hampton Research) 
and JCSG+ (Qiagen), ultimately the latter of which resulted in visible 
micro-crystals of Epa7 (Figure 2.11, A). Epa7 crystals grown by hanging 
drop vapor diffusion are shown in panel A (Figure 2.11) and verified as 
from protein of interest through Western-blot analysis panel B. To 
remove the ambiguity of protein vs. salt crystals a couple of crystals were 
gathered for confirmative testing using our Epa1 N-terminal specific 
antibody (#3638) in panel B (Figure 2.11). Regrettably, the crystals were 
tested for X-ray diffraction but yielded poor resolution data (about ~ 7Aº). 
Encouraged by our progress, optimization experiments were underway to 
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obtain properly packed protein crystals. However, during this time the 
protein structure of Epa 1 was published24 by Ielasi et.al. 2012 and the 
structural biology part of the project was stopped.  
2.2.4 Purification of EPA gene family proteins 
      The Cormack lab has previously shown the adhesin ligand 
specificities of the adhesin proteins Epa1, Epa6 and Epa7 through cell-
based experiments using fusions to the C-term domain of Cwp219 a GPI-
CWP that is important for the membrane structural stability of S. 
cerevisiae. The N-terminal domains were expressed along the cell surface 
of intact S. cerevisiae.19 While this heterologous expression system 
worked well there still remained a lack of ligand binding information from 
natively expressed proteins. We sought to determine the glycan binding 
specificities through the expression of the entire EPA gene family. Of the 
25 gene members 20 constructs of the N-terminal domain were 
successfully created and subcloned using restriction enzymes BamHI 
and XhoI for directional cloning or compatible BglII and SalI fragments 
(detailed in Table 2.4). The exact cloning regions were determined after a 
multi-sequence alignment for all EPA gene members was created. The 
alignment was made using the open resource T-coffee 
(http://tcoffee.crg.cat). Conspicuously, the alignment reveals the 
potential presence of the lectin binding domain known to be present in 
Epa1, Epa6 and Epa7 may also be present in several Epa protein family 
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members (Figure 2.10). Eleven of the 20 proteins were expressed as 
6xHis-Sumo fusions and secreted from HEK 293 (GNTI-) cells. A 
summary of the expressed proteins is shown in Coomassie stained gels 
(Figure 2.9). All protein fragments were made as His-Sumo1 fusions with 
the exception of Epa1, Epa6 and Epa7 (not shown), which are additional 
versions possessing a simple 6xHis tag. We ultimately obtained glycan 
specificities for 6 gene family members, namely EPAs: 1, 6, 7, 12, 23, and 
25. These results are summarized on Table 2.5 – Glycan Microarrays.  
2.2.5 Glycan microarray analysis (EPA1, EPA6 and EPA7) 
      With 50% or more of all proteins carrying glycan chains, glycomics 
has emerged as an area of intense investigation in the post-genomics 
era.25 Glycan microarray analysis is a high-throughput approach for 
determining the ligand-binding specificities of a range of glycan binding 
proteins (lectins). For this current work we used printed glycan arrays 
developed by the Consortium for Functional Glycomics (CFG; 
http://www.functionalglycomics.org), to screen purified proteins of the 
EPA gene family. Glycan specificities were obtained for the following 
EPAs: 1, 6, 7, 12, 23 and 25 using two different protein concentrations 
(50 µg/mL and 200 µg/mL). Prior to analysis the proteins were 
fluorescently labeled by conjugation with the Alexa-Fluor 488 dye for 
detection. The printed arrays contained both natural and synthetic 
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carbohydrate structures for a total of 612 unique glycans representing 
the major glycoprotein and glycolipid structures.  
 
      Our analysis show that all three recombinantly expressed lectin 
domain proteins: Epa1, Epa6 and Epa7 all bind to galactose terminal 
end ligands which is generally in keeping with previous overall results 
from glycan microarray experiments. For determining the differences 
between ligand specificities, the non-reducing galactose end sugars were 
placed into subcategories defining certain features within terminal 
disaccharides such as: type of anomeric conformation, the linkage 
position of the hydroxyls involved, identity of the penultimate residue, 
modifications of these residues (i.e. Sialylation, N-acetylation, Sulfation) 
and/or presence of branched structures.  
 
      Our results indicate preferential binding by Epa1 and Epa7 primarily 
to β-type glycan linkages, which corroborates with previous results from 
our lab, specifically β1-3 linked galactosides (Figure 2.12 Ai, ii). A new 
distinction from earlier experiments that showed Epa6 binding equally 
well to β and α-type linkages, our current analysis shows Epa6 strongly 
prefers binding to the α-linkage class. Within the β-linked class, another 
divergence from previous results where no preference between β1-3 or 
β1-4 linkages was found, our current findings for all three adhesins 
(Epa1, Epa6 and Epa7) show a strong affinity for β1-3 type linkages. All 
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three adhesins proteins show a similarly strong predilection for β1-3 
linkage, essentially exclusive for β1-3 type bonds (Figure 2.12Aii). 
According to previous studies within this Galβ1-3 sub-category, there 
was a strong affinity by Epa1 for GalNac in the penultimate position, ‘the 
T-antigen’. Our current data continues to support this as true, yet the 
selectivity over the unmodified galactose (GalNAc) is much more 
pronounced for Epa7 rather than Epa1 (Figure 2.12 Aiii). Interestingly, 
within this β1-3 type linkage group all three adhesins Epa1, Epa6 and 
Epa7 show an aversion for GlcNAc in the penultimate position compared 
to GalNAc (Figure 2.12Aiv). The difference between galactose and glucose 
is due to the C4-OH orientation; this subtle difference reflects the refined 
specificity that has been attained by C. glabrata adhesins. Epa6 
highlights this idea by not only preferring α-type bonds but also 
possessing the capacity to bind Gal β1-3 type linkages over β1-4 types. 
Clearly the β1-4 bond presents a binding barrier for all three adhesins 
and the penultimate residue appears to serve an important role in 
binding criteria as well. Both Epa1 and Epa7 prefer the penultimate 
galactose to be N-acetyl modified and when the modification takes place 
on the penultimate position, the type of residue dictates binding success. 
All three adhesins bind preferentially to galactose rather than glucose 
(Galβ1-3GalNAc vs. Galβ1-3GlcNAc).             
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      The linkage orientation between the terminal galactose and the 
penultimate residue is a key aspect in ligand recognition. As mentioned 
above, the Gal β1-3 type linkage is preferred over β1-4 types, yet within 
this β1-4 subcategory we find very strong selectivity characteristics as to 
the identity of the penultimate residue and whether or not the 
penultimate residue is modified. Further analysis of the β1-4 subcategory 
shows that glucose (Galβ1-4Glc) in the penultimate position is robustly 
preferred over galactose (Galβ1-4Gal) and if the glucose residue is N-
acetyl modified than even more so than the unmodified glucose (Figure 
2.12Bi,ii, iv). This modification selectivity along the penultimate position 
(Figure 2.12Biii) is favored even when the identity of the residue is a 
galactose (Galβ1-4GalNAc). Interestingly, this N-acetyl modification at the 
penultimate position is an important general binding feature since all 
three adhesins (Epa1, Epa6, Epa7) bind strongly and selectively 
compared to the simple unmodified sugar whether it is glucose or 
galactose (Figure 2.12 Biii, iv). Thus, creating a β1-4 type bond with 
glucose averts the C4-OH orientation that is inhibiting for a β1-3 glucose 
type linkage (Galβ1-3Glc). This is unlike what we see with the β1-3 bond 
where galactose is preferred, which is reasonable considering the axial 
C4 hydroxyl-orientation of galactose. When assessing the influence of the 
glycan bonds on N-acetyl modified sugars at the penultimate position we 
see some clear distinctions. As mentioned previously in a β1-3 
conformation the three adhesins will bind to GalNAc compared to 
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GlcNAc, unless the bond is a β1-4 linkage type, in which case Epa6 and 
Epa7 will be selective for glucose (GlcNAc); Epa1 maintains a modest 
affinity for GalNAc (Figure 2.12Bii). This is a sharply different result from 
previous analysis that report an inability for this set of adhesins to 
distinguish between Galβ1-4Glc and Galβ1-4GlcNAc. This general 
binding feature is true also in the β1-3 category for Epa1 and Epa7 
although not as pronounced.  
 
      All three adhesins appear to require galactose in the penultimate 
position. Epa1, Epa6 and Epa7 bind exclusively to Gal – Gal or Gal – 
GalNAc glycans but strictly when the bond is of the β1-3 nature and not 
the β1-4 linkage type (Figure 2.12Ci,ii). Notably, when the penultimate 
residue N-acetyl modified and the identity is glucose (Gal – GlcNAc) then 
the β1-4 linkage is strongly preferred by Epa1 (Figure 2.12 Ciii); Epa6 
and Epa7 show no bond type preference when the penultimate residue is 
glucose (GlcNAc). Therefore, as mentioned earlier, a single OH-
reorientation can create a large difference in adhesin ligand recognition.  
 
      One particular modification feature on glycans that creates a strong 
preference or strong inhibition for adhesin binding recognition is the 
presence of sulfation (S). Selectivity is also influenced by the position and 
the number of the sulfate marks on different glycan residues. The 
presence of sulfation appears to dominate within the β1-4 linkage 
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category, but only Epa1 seems to possess an affinity for this modification 
although under very specific conditions (Figure 2.12Di-iv). Epa1 will bind 
to a terminal sulfated-Gal (Figure 2.12Di,ii) but not in the presence of 
two sulfates ((6S)(3S)Galβ1-4GlcNAc). It will also be inclined to bind a 
penultimate sulfate mark (Figure 2.12Diii,iv) if the linkage is a β1-3 type; 
Epa6 will also work if it is a β1-4 bond (Galβ1-4(6S)Glc). The Epa1 
binding range is exhibited not only by its capacity to bind (S) glycans on 
two different sugar types but also on two conformations; β1-3 and β1-4 
bonded glycans. Epa6 and Epa7 share a similar binding profile to this 
glycan but show a clear preference for the non-sulfated GlcNAc. These 
nuanced binding features can be uncovered continuously, but what we 
can conclude is that sulfation within this set of adhesins does not play a 
significant role in binding as it does with Epa12, Epa23 and Epa25, 
discussed below. 
     
      Finally, Epa1 and Epa7 possess virtually no binding capacity for α-
type linked glycans, which contrasts completely with Epa6, which shows 
a strong preference for α-types. All three adhesins show similar binding 
profiles for various α-types regardless of linkage position or penultimate 
sugar identity (Galα1-3, Galα1-4), except for Galα1-3fucosyl substituted 
glycan that is strongly disfavored by both Epa6 and Epa7 compared to 
Epa1 (Figure 2.12 Civ). This is merely a technical point considering the 
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small relative fraction of α-type linked glycans to which Epa1 and Epa7 
bind but again emphasizes the importance of penultimate modifications.  
2.2.6 Glycan microarray analysis (EPA12, EPA23 and EPA25) 
      Our analysis show that all three recombinantly expressed lectin 
domain proteins: Epa12, Epa23 and Epa25 all bind to galactose terminal 
end ligands which is generally in keeping with previous results from 
glycan microarray experiments. For determining the differences between 
ligand specificities, similar categories and subcategories were compared 
as the above analysis with Epa1, Epa6 and Epa7. 
 
      Unlike Epa1, Epa6 and Epa7, which preferentially bind to β-type 
linkages, Epa12, Epa23 do not. While Epa25 does prefer β-type links it 
does also have the capacity to bind α-type glycans. There are some 
characteristic distinctions that distinguish these adhesins from the prior 
set of proteins. In general there are more modest binding specific profiles 
regarding the type of linkage, the bond position (C4 vs. C3), the identity 
of the penultimate residue and a diminished influence of N-acetyl 
modified penultimate residues when compared to the above discussed 
set of adhesins.  
 
      Our newest set of Epa proteins certainly have a similar general 
binding specificity for glycans with terminal galactoses however they 
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display a predilection toward α-type linkages rather than the β-type 
conformation, particularly for Epa12 and Epa23 (Figure 2.13Ai). Within 
the α-type linkage class, all three adhesins (Epa12,23,25) prefer the C-4 
hydroxyl position (Figure 2.13Aii), contrary to the C-3 of the above set of 
adhesins, a likely consequence of steric constraints. When comparing 
Epa12, Epa23 and Epa25 to the earlier set of adhesins we can see that 
there must be some general structural features between both sets of 
proteins that allow for some general ligand binding requirements. This 
new set of adhesins appears a bit more forgiving as to the type of linkage 
or the identity of the penultimate sugar. While Epa1, Epa6 and Epa7 
maintain an exclusive affinity for β type links, specifically β1-3 linkages, 
Epa12 and Epa23 likewise prefer β1-3 linkages yet possess the capacity 
for binding β1-4 types as well (Figure 2.13Aiii). Additionally, within this 
subclass (β1-4) all three adhesins show a preference for a N-acetylated 
penultimate glucose over the unmodified sugar; Galβ1-4GlcNAc vs. 
Galβ1-4Glc (Figure 2.13Aiv). 
 
      Within the β-type category the nature of the glycosidic bond and the 
identity of the penultimate residue appears to be most critical for Epa25 
binding. Modifications of the penultimate residue as opposed to the 
terminal galactose also seem to be a distinguishing selection 
characteristic for Epa25 binding as it possess the most selective binding 
range than does Epa12 and Epa23. Furthermore, Epa25 shares a similar 
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binding profile as the above Epa7 adhesin, in that they both have a 
unique preference for the ‘T – antigen’ Galβ1-3GalNac (data not shown). 
These ligand binding distinctions regarding linkage types and C-positions 
reveal significant structural differences between this current set of 
adhesins and the former set (Epa1, Epa6, Epa7) that are clearly borne 
out by the strong preference for sulfated modifications along the ultimate 
and penultimate glycan positions. Interestingly, while Epa6 also prefers 
α-type linkages it can only bind preferentially to sulfated modifications 
under specific circumstances; when the sulfate is on the penultimate 
glucose residue. 
 
      In sharp contrast to the above set of adhesins where only Epa1 
shows strong binding to terminally sulfated glycans Epa12, Epa23 and 
Epa25 all show strong, avid binding for sulfated terminal galactoses 
(6S)Galβ1-4Glc+/-NAc (Figure 2.13 Bi-iv). When a second modification 
adds an additional negative charge to the terminal galactose by way of 
sulfation this becomes inhibitory for Epa25 binding (6S)(3S)Galβ1-
4GlcNAc, however, it is clearly preferred by Epa12 and Epa23. In 
addition to showing a strong propensity to bind to terminal galactose 
residues, all three EPA genes (Epa12, Epa23, Epa25) also bind 
preferentially to the penultimate (S) modified glucose (Figure 2.13 Biii). 
Moreover, sulfation at both the terminal (6S)Gal or penultimate residue 
GlcNAc(6S) is preferred by all three adhesins Epa12, Epa23, Epa25. 
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Therefore, the capacity to bind glycans sulfated at either the terminal or 
penultimate residue indicates that it is likely that these adhesins share 
some common structural binding motif that allows for these negative 
sulfate groups to be accommodated at either position. One exception to 
the overall binding preference to sulfated glycans by this set of adhesins 
is Epa12, which shows strong aversion for the penultimate (S) modified 
GlcNAc though only when it occurs in the β1-3 configuration (data not 
shown). Finally, an analysis of the α-type binding category shows that 
Epa12, Epa23 and Epa25 prefer binding to α1-4 type linkages, unlike 
the previous set of adhesins that prefer β-type bonds. 
 
      The most compelling result from the following glycan-array analysis 
is the fact that this new set of adhesins analyzed (Epa12, Epa23 and 
Epa25), clearly have a strong bias for sulfated glycans. And the (S) 
modification can occur at the terminal galactose, the penultimate residue 
or both with either a single (S) modification or even double (S) 
modifications. This is a keen distinction from earlier adhesins analyzed 
(Epa1, Epa6 and Epa7) where ligand binding to sulfated glycans occurs 
only under a very limited number of circumstances.   
 
      The results highlight and emphasize previous findings using 
heterologous expression of Epa1, Epa6 and Epa7 in whole S. cerevisiae 
cells. Some discordant findings are somewhat expected considering the 
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increased range of glycan structures probed in the current arrays 
pertaining to these studies, that is, the present arrays contain twice the 
number of glycans used in previous glycan-chip profiling experiments 
Table 2.5.  
2.3 Discussion 
      C. glabrata survives as a commensal organism in humans until the 
appropriate conditions present themselves whereby its ‘Jekyll and Hyde’ 
persona is exposed and assumes an opportunistic pathogenic existence.  
The mechanism of adhesion is based on several important factors. The 
type of proteins expressed by the fungal pathogen, the type of host cells 
present on the organism and the conditions presently that will be 
permissible for colonization. The first step in fungal colonization and 
invasion of host tissues is the adherence of Candida spp. through a set of 
proteins collectively known as adhesins. A proteomics and bioinformatics 
analysis of the C. glabrata genome has revealed a set of 67 adhesin-like 
proteins of which 2/3 are subject to subtelomeric regulation. Depending 
on the C. glabrata strain and nutrient sufficiencies there will be 23 to 26 
gene members held in a transcriptionally repressive state. These are the 
primary mediators of adhesion belonging to the EPA (epithelial adhesin) 
family of proteins, the largest of seven subgroups identified. Much of the 
success of C. glabrata as a pathogen is owed to its repertoire of adhesins 
and to the inherent capacity of expansion and allele variability within the 
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adhesin gene families that is likely created during DNA recombination 
events. Adhesins are known as virulence factors that contribute 
significantly to the pathogenicity of C. glabrata as well as C. albicans (Als 
protein family).  
 
      Identification of a highly stable protein fragment within the lectin-
binding region of Epa1, Epa6 and Epa7 (S40-I283, W40-V283 
respectively) was revealed during the cloning and expression optimization 
experiments. These early results imparted an initial indication of the 
importance of disulfide bridges to the overall stability and architectural 
integrity of this N-terminal domain. Recent data from the solved crystal 
structure of Epa1 indicate that both the N-terminus and C-terminus are 
bound to the main body of the protein by disulfide bridges, one between 
Cys50 and Cys179 and the second between Cys180 and Cys262. This 
arrangement gives the protein a more compact shape and blocks access 
to the space between two central sheets thereby decreasing the surface of 
the β-sandwich exposed to the solvent. The overall structure of the 
barrel-shaped Epa1-NT domain is of an antiparallel β-sandwich motif 
composed of 15 β-strands, 11 of which encompass the PA14 domain. The 
remaining 4 β-strands along with the termini wrap around the sandwich 
and help limit access to solvent. The reported binding site is mediated by 
a series of 5 loops that utilize a unique DcisD motif to help coordinate 
Ca2+ for direct interaction with hydroxyl groups essential for glycan 
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specific binding. Another critical disulfide bridge crosslinking two loop 
fragments (Cys78 and Cys119) appears to be very important in shielding 
the Epa1-NT active site from the external environment necessary for 
efficient and specific binding to carbohydrate ligands. A similar layout is 
also employed by the S. cerevisiae homolog Flo5A, whereby a unique 
subdomain together with a second loop help seal the surface of the 
underlying β-sheet from solvent access24,26,27. In addition to limiting 
solvent access to the active site another characteristic afforded by these 
cysteine linkages may be to provide rigidity to the overall protein to 
facilitate binding along the extracellular surface of the cell. This 
conserved shared strategy suggests a general feature that may be 
significant for GPI linked cell-wall-protein adhesins. 
  
      Results from glycan-array profiling experiments provide further 
evidence behind the nature of Epa-specific binding to host epithelial and 
endothelial cell types. The overall results are consistent with previous 
reports and help emphasize the importance of determining the glycan 
specificities for all members of the EPA gene family. One of the most 
pronounced outcomes among all adhesins studied to date is the 
overwhelming preferential binding of Epa1 and Epa7 for β-linked 
galactosides over α-type linkages. The αGal epitope (Galα1-3Gal) 
modified glycoproteins and glycolipids can be found in all mammals 
except humans, apes and old world monkeys28,29. One straightforward 
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explanation offered is that, evolutionary processes have resulted in loss 
of the gene necessary for expressing these αGal markers on their cells. In 
turn, C. glabrata has evolved along with humans to develop sugar-
binding specificities that delineate its environment. It would be of some 
interest to compare C. glabrata strains in animals with the strains found 
in humans to see how the EPA family of adhesins has evolved if at all to 
any significant extent. Furthermore, of physiological relevance is the 
preference of Epa1, Epa7 and Epa25 for the T-antigen (Thomsen-
Friedenreich), Galβ1-3GalNac glycan. It is a main core structure found in 
glycoconjugates of mucin type proteins – a high molecular weight family 
of proteins that are secreted by epithelial cells as principal components 
of mucus. Yet another sugar moiety found abundantly along the 
mammalian digestive tract is the glycan GlcNacβ1-3GalNac that is 
curiously of low affinity to the Epa adhesins analyzed herein. With the 
exception of Epa1, which showed marginal capacity for terminal GlcNacs 
(data not shown), all of the Epa proteins tested in this study displayed a 
strong predilection for terminal galactose glycosides. Binding analysis of 
these adhesins allows for a much sharper picture of the manner in which 
C. glabrata is able to survive as part of the human gut and/or exploit 
characteristics associated with constituents of the microbiota.   
 
      Contrary to the previously analyzed set of EPA genes, the recent 
glycan specificity data for Epa12, Epa23 and Epa25 precedes an 
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extensive body of biological data. Apart from potential adhesion 
redundancy, the physiological roles for these EPAs are unknown. In like 
manner, a fundamental understanding of the regulatory mechanisms 
controlling the expression of each of these family members remains to be 
fully established. Cell binding data produced from our lab has 
established some initial indications as possible cellular adhesins; yet 
much work remains to be developed to arrive at a contextual framework 
for the functional mechanisms for this set of EPA genes.  
 
      Our results point to the fact that it is of some consequence that the 
Epa12, Epa23 and Epa25 are especially inclined to bind to sulfated 
terminal disaccharides. Sulfated glycans play important roles in 
biological function such as homing of lymphocytes30,31 and adhesion of 
neural cells.32 Heparin – a heavily sulfated GAG (glycosaminoglycans) is 
known to be one of the most negatively charged polymers of natural 
occurrence, an essential feature allowing for its participation in many 
molecular and cellular events in inflammation.33 Recognizing the general 
localization of the EPA gene family – one conceivable interpretation is 
that evolution of C. glabrata throughout its human residency has 
rendered a subset of genes (EPAs: 12, 23, 25) studied thus far with the 
capacity to co-opt a similar strategy utilized by human leukocytes for 
obtaining access to endothelial cell types at sites of inflammation. The 
routine use of clinical catheters is intimately associated with chronic 
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activation of the immune and inflammatory system.34 This work suggests 
Epa-mediated binding to sulfated glycans may provide a link between C. 
glabrata UTIs, catheterization and candiduria, in hospitalized 
patients,35,36 in whom indwelling catheters are a very important risk 
factor.  
 
      Sulfated polysaccharides are actively being analyzed as drug 
candidates for protozoan infectious diseases,37,38 along with sulfated 
proteoglycans and glycosaminoglycans (GAGs) both of which are known 
targets of a number of infectious diseases with significant health 
consequences in immune-competent humans. GAGs are found on the 
surface of almost all cell types and are used by many intracellular 
pathogens to attach and gain entry to host cells.39 Microsporidia are 
opportunistic protists that infect a wide variety of animals, including 
humans. Encephalitozoon intestinalis exploits sulfated glycans such as 
the cell surface (GAGs) in selection of and attachment to host cells.40 
Other eukaryotic microbes utilizing a similar targeting strategy like 
Plasmodium falciparum bind heparin and heparin sulfate,41,42 allowing for 
the infection of hepatocytes and the placenta. The success of Toxoplasma 
gondii infection is attributed to its ability to bind a wide variety of host 
GAGs.43 The bacterial pathogens Listeria monocytogenes 44 and 
Mycobacterium spp.45 also bind cell surface heparin for adherence to 
epithelial cells. The dengue 46 and foot and mouth disease viruses also 
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interact with heparan sulfate.47 The parasites Trypanosoma cruzi,48 
Plasmodium spp.,41 and Leishmania spp.49,50 are reported to use heparan 
sulfate in host cell adhesion. In all, binding to host cell surface sulfated 
targets is an established adhesion mechanism that might also be 
employed by specific EPA family members of C. glabrata.  
 
      It should be noted that the binding profiles obtained here through 
heterologous expression of the core lectin binding domain alone lacks the 
native structural components that have been shown critical for the 
function as adhesion proteins. Explicitly, the lack of its heavily O-
glycosylated central domain which is known to impart physical rigidity to 
the N-terminal binding region could be influencing the extent of binding 
variability in our analysis. A set of complementary cell based experiments 
utilizing exogenously expressing fusion proteins to the Cwp2 C-terminal 
domain of S.cerevisiae as demonstrated in earlier work should be 
undertaken to help support current findings.  
 
      One final consideration regarding the recently published Epa1 
structure concerns the manner in which the protein was generated. The 
reasons behind our painstaking efforts for developing a eukaryotic 
expression system was due to the knowledge of the fact that Epa1 
undergoes several post-translational modifications, principally – 
glycosylation. Recent binding affinity differences between the Epa1 lectin 
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homologs Flo1, Lg-Flo1 and Flo5 exposes the affects of deglycosylation on 
substrate binding affinities.51 The latter recombinantly expressed in 
Escherichia coli and the first two in yeast. Thus it remains to be seen if 
the current structure of Epa1 produced in E. coli is physiologically 
consistent and compatible with binding selectivity of our EPA adhesins 




Figure 2.1 Secondary Structure Prediction of C. glabrata EPA1 NT 
(ATG-K350). 
Green arrows indicate N-terminal start sites. Orange arrows indicate C-
terminal stops. The single letter amino acid sequence shown is numbered 
(above) along with probability estimates (below) for secondary structure 
features. (The more likely the feature the higher the number value 0 – 
10). Constructs were designed as indicated by green and orange arrows 
with a general cloning strategy to avoid the disruption of structured 
domains such as extended β-sheets and/or unordered loop regions. 
Specific construct domains are detailed in Table 2.1.  






Figure 2.2 Schematic representation of the cloning of His-Sumo-
Epa1 NT fusion 
Protein expressed in E. coli. (BL21-DE3). Epa 1 fragments are 
immediately downstream of Sumo (Smt3) and designed to be cloned in-
frame by specific usage of the BamHI restriction site. The system allows 
for removal of the Sumo protein along with the polyhistidine affinity tag 
by way of the Ulp 1 (Ubiquitn-like specific protease) protease that 
specifically recognizes the terminal Gly-Gly sequence of Sumo. After 
cleavage, the result is the incorporation of a non-native Serine residue 5’ 
to the native sequence.  
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Figure 2.3 SDS PAGE gels of Epa 1 NT fragments.  
Coomassie stained gels of a panel of His-sumo Epa1 (N-terminal) fusion 
proteins. Samples were run from lysates of E. coli strains of various 
stages along the expression tests. Lane numbers correspond to different 
protein constructs of Epa1 as detailed in Table 2.1.  
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Blue bracket indicates the range of expected Epa1p fragments sizes (~ 32 
– 52 kDa) including the Sumo tag and potential glycosylation.  
(M lane = protein standards marker).  
A, B. Imidazole Elutions, M, Elutions, M, Resin bound fractions (boiled 
off in1xLB).  
C, D. Resin bound, M, Induced proteins, M, Un-induced fractions.  













Figure 2.4 Coomassie stained gel of EPA1 construct #2 (A30-S274).  
Using the various buffer conditions listed on Table 2.2, samples were Ni2+ 
affinity purified. Numbered lanes correspond to separate buffers used 
during the purification process. (M – prestained protein molecular 
weights standards). Small-scale batch purifications were made whereby 
one large culture (150 mL) was pelleted in 10 mL fractions at which point 
the testing buffers (Table 2.2) were added and carried thru the affinity 
purification process. No clear benefit was afforded. Protein appears to 










Figure 2.5 Coomassie stained gels of a series of Epa1 NT fragments 
(20)  
Expressed in adherent HEK293 GNTI- cells and purified by Ni2+-NTA 
affinity, using the mammalian expression plasmid pαSHP-H. (For clarity, 
composite figures were created to maintain continuity of results). 
Numbered lanes correspond to different Epa1p-Nterm domains as 
indicated. Two sets of samples run #1-20. A. Elutions – Imidazole (250 




Figure 2.6 Mass Spectrometry Analysis and Coomassie stain insert 
of Limited Proteolysis of Epa1.  
Coomassie stained PVDF blot of Epa1.5 protein treated with various 
concentrations of Proteinase K along with an UC (uncut) control. These 
bands were excised and processed for mass-spectrometry analysis. Mass 
spectrum analysis yields a “peptide fingerprint” that identifies a very 







Figure 2.7 Coomassie and Western of Epa 1, 6, 7 and Epa1.5 
transfection trials.  
Small-scale mammalian expression of Epa proteins is low yielding. Lane 
descriptions are detailed in Table 2.3. Coomassie gel shows faint banding 
not captured in the image. Western blot indicates domain size difference 
between Epa1 and Epa1.5 as expected. Also evident on Western are 
presumably distinct glycosylation patterns between Epa1, Epa6 and 
Epa7 resulting in pronounced separation in PAGE gel migration patterns. 
Apparent ‘burn thru’ or halo effect of bands on film is due to overloading 
or overexposed Western blot. 
1º ab. anti-NT Epa1 #3638 (rabbit polyclonal lab stock, dilution 1-10K).  
2º ab. Mouse anti-rabbit ab. (dilution 1-10K). 






Figure 2.8  2-Step Purification and Size Exclusion Chromatography 
Coomassie gel insert of Epa1 (S40-I283) production in HEK293 GNTI– 
cells. Sample fractions collected along IMAC (immobilized metal affinity 
chromatography) step followed by sample fractions of the lectin-binding 
step using Lactose-sepharose resin. The lac-sepharose elutions were 
passed over a diagnostic size-exclusion chromatography column (S75). 
The UV (ultraviolet-280nm) trace peak indicates appropriate sizing profile 
considering glycosylation features of Epa 1. Functionality is also inferred 
by the absence of protein in the initial void volume. (M- prestained 
protein molecular weights standards, W- wash, UC- uncut, R- resin, FT- 
flow thru, E- elutions).   
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Figure 2.9 Coomassie stained gel of EPA family of NT domain 
fragments. (Composite figure)  
Proteins were made as secreted His-Sumo1 fusions in HEK-293 cells, 
using the pαSHS mammalian expression plasmid. Epa1 and Epa6 were 
also made as non-fusions with only a His tag using pαSHP (Epa7 not 
shown). Not all proteins were successfully expressed, those confirmed by 
Western analysis continued on for glycan array analysis. (SHS- signal 
sequence 8xHis Sumo1, SHP- signal sequence 8xHis prescission site). 
Glycan-chip experiments were conducted by the CFG (Consortium for 








Figure 2.10 EPA Gene Family Amino Acid Sequence Alignment. 
C. glabrata EPA gene family sequences – 25 in total, were assembled into 
a multi-sequence alignment program T-coffee. Numbered amino acids are 
labeled on top correspond to the longest sequence present (Epa20) and 
consensus amino acids are displayed below. Higher homology is depicted 
in red lettering and conserved residues of lesser consensus are depicted 
in blue lettering. Many key residues identified as part of the PA-14 
domain within the N-terminal domain of Epa1 are also laid out along the 




Figure 2.11 Epa7 protein crystals and Western blot analysis. 
A. Hanging drop vapor diffusion technique was used to obtain visible 
crystals. Initial crystallization trays were set using the Qiagen JCSG+ 
(Joint Consortium for Structural Genomics) commercial screens. Crystals 
were differentiated after about one week at 30ºC in drops with a protein 
concentration of 6 mg / ml in wells and a reservoir solution of 50% PEG 
4000, 0.1M NaCl, 0.2M Li(SO4)2. B. Western of protein crystal of Epa7; 
crystals were recovered and run on PAGE for subsequent confirmation 
with anti EpaNT rabbit polyclonal ab (lab stock #3638). The lane on the 
right side of the protein standards marker is a negative control, the 












Figure 2.12 Epa1, Epa6 and Epa7 comparisons of normalized 
averaged rfu (relative fluorescent units) for various sugar 
categories from glycan microarrays.  
Numbers in parenthesis indicates the number of glycans used in the 
comparison. A. Analysis of the anomeric configuration of each linkage (α 
or β) between the non-reducing end (terminal galactose) and the 
penultimate residue on the binding specificity and of the linkage position 
between the carbon numbers of the hydroxyls involved. (i) Comparison of 
glycans containing a terminal galactose residue linked to the penultimate 
residue by a β-linkage (Galβ) or α linkage (Galα). (ii) Comparison of 
glycans containing a terminal galactose residue linked to the penultimate 
residue by a β1-3 (Galβ1-3) or β1-4 (Galβ1-4) linkage. (iii) Comparison of 
glycans containing a terminal galactose residue linked to the penultimate 
residue by a β1-3 (Galβ1-3) linkage and the various penultimate residues 
(Gal, GalNAc). (iv) Comparison of glycans containing a terminal galactose 
residue linked to the penultimate residue by a β1-3 (Galβ1-3) linkage and 
varying penultimate residues galactose or glucose and the influence of N-
acetylated (NAc) modifications (GalNAc, GlcNAc). B. Analysis of the 
Galβ1-4 configuration subcategory with various penultimate residues on 
binding specificity. (i) Comparison of glycans containing a penultimate 
glucose or galactose residue (Galβ1-4Gal, Galβ1-4Glc). (ii) Comparison of 
glycans containing a penultimate N-acetylated modification on either a 
glucose or galactose residue (Galβ1-4GalNAc, Galβ1-4GlcNAc). (iii-iv) 
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Comparison of glycans and N-acetyl modification of galactose or glucose 
(Gal β1-4Gal, Galβ1-4GalNAc) and (Galβ1-4Glc, Galβ1-4GlcNAc). 
C(i-iii). Analysis of the influence of the type of bond β1-3 or β1-4 attached 
to various penultimate residues (Gal, GalNAc, GlcNAc). C(iv). Analysis of 
the linkage position of the α conformer category. Comparison of glycans 
of the α configuration class and the linkage types (Galα1-3, Galα1-4, 
Galα1-3 fucosyl substitution) D. Analysis of the modified terminal 
disaccharides by sulfation at the non-reducing galactose end, and/or the 
penultimate positions as well as the influence of N-acetylation on the 
penultimate residue (6S, 3S, NAc). (i) Comparison of glycans with the 
presence of sulfation at the terminal galactose and N-acetylation 
modifications on the penultimate glucose. (ii) Comparison of glycans with 
a (Galβ1-4GlcNAc) and the presence of two sulfation modifications (6S, 
3S) at the terminal non-reducing end. (iii, iv) Comparison of glycans with 
varying positions of the galactose-β linkage (Galβ1-4(6S)Glc) and sulfated 






Figure 2.13 Epa12, Epa23 and Epa25 comparisons of normalized 
averaged rfu (relative fluorescent units) for various sugar 
categories from glycan microarrays.  
Numbers in parenthesis indicates the number of glycans used in the 
comparison. A. Analysis of the anomeric configuration of each linkage (α 
or β) between the non-reducing end (terminal galactose) and the 
penultimate residue on the binding specificity and of the linkage position 
between the carbon numbers of the hydroxyls involved. (i) Comparison of 
glycans containing a terminal galactose residue linked to the penultimate 
residue by a β-linkage (Galβ) or α linkage (Galα). (ii) Comparison of 
glycans containing a terminal galactose residue linked to the penultimate 
residue by a β1-3 (Galβ1-3) or β1-4 (Galβ1-4) linkage. (iii) Comparison of 
glycans containing a terminal galactose residue linked to the penultimate 
residue by a β1-3 (Galβ1-3) linkage and the various penultimate residues 
(Gal, GalNAc). (iv) Comparison of glycans containing a terminal galactose 
residue linked to the penultimate residue by a β1-3 (Galβ1-3) linkage and 
varying penultimate residues galactose or glucose and the influence of N-
acetylated (NAc) modifications (GalNAc, GlcNAc). B. Analysis of the 
Galβ1-4 configuration subcategory with various penultimate residues on 
binding specificity. (i) Comparison of glycans containing a penultimate 
glucose or galactose residue (Galβ1-4Gal, Galβ1-4Glc). (ii) Comparison of 
glycans containing a penultimate N-acetylated modification on either a 
glucose or galactose residue (Galβ1-4GalNAc, Galβ1-4GlcNAc). (iii-iv) 
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Comparison of glycans and N-acetyl modification of galactose or glucose 








Table 2.1 EPA 1 – NT domain expression constructs and expected 
protein molecular weights (Daltons). 
Epa1 lectin domain fragments were cloned into a modified pET28a 
plasmid as 6xHis-Sumo1 N-terminal fusions. Directional cloning of 
fragments made by BamHI – XhoI restriction sites. Constructs were 




Table 2.2 Varying parameters for solubility.  
A series of biophysical parameters were tested to improve folding 
behavior of Epa1p. The 11 buffers focused on: salt, pH, reducing capacity 





Table 2.3 General small-scale transfection protocol. Expression 
tests for Epa 1, 6, 7 and Epa1.5 performed in HEK293 GNTI- cells 
using 6-well plates.  
Epa proteins expressed as secreted fusion proteins (pα SHS – Signal 
sequence, 8xHis, Sumo-1). Transfections carried out when cells are 
approximately 80% confluent. (PEI-polyethylinimine, HSFM- hybridoma 
serum free media). Protocol is detailed in methods.  
• DNA and PEI (mixed at 1:2 mass ratio) complexes are allowed to 
proceed in HSFM, incubated for 10 min, then added back to 1xPBS 
washed cells.  
• Cells are harvest 4da post transfection 
• Ni2+ purification 
• Ulp1 digest overnight 







Table 2.4. List of oligos for Epa family of N-term fragments 
expressed as His-Sumo fusions.  
Above oligos made with BamHI and XhoI restriction sites for directional 
cohesive-end cloning, compatible with Dan Leahy’s (JHU) pα SHP-H or 
pα SHS (Cormack-lab Sumo version) mammalian expression plasmids. 
Alternative BglII and SalI restriction sites were also used in some cases 




Table 2.5 Glycan Microarray Table. 
Glycan array data from purified N-terminal domains of Epa1p, Epa6p, 
Epa7p, Epa12p, Epa23p and Epa25p expressed in HEK 293 (GNTI-) cells. 
Data was obtained at two different protein concentrations as indicated 
(200 µg/ml and 50 µg/ml). Numbers indicate average relative 
fluorescence units (rfu) for each sample. Rfu values of the top 5% are 


































136 Neu5Aca2-6(Galb1-3)GalNAca-Sp8 9731 2515 7012 9 22 234 557 195 4229
137 Neu5Aca2-6(Galb1-3)GalNAca-Sp14 4443 1770 4226 17 16 593 54 69 2308
140 Galb1-3GalNAca-Sp8 3620 4817 2408 2 10 6 395 765 1472
146 Galb1-3GalNAcb1-4Galb1-4Glcb-Sp8 1686 2446 14186 34 18 674 541 2064 3186
141 Galb1-3GalNAca-Sp14 1568 4342 1572 8 9 280 67 452 567
142 Galb1-3GalNAca-Sp16 1550 2139 888 13 10 7 68 134 503





4Glcb-Sp0 1283 4230 1269 7 11 6 2 449 622




Sp8 856 4228 3095 2 15 8 342 995 495
42 (6S)Galb1-4Glcb-Sp0 819 57 32 135 317 227 14 49 9
138 Neu5Acb2-6(Galb1-3)GalNAca-Sp8 810 642 1053 3 9 6 1 15 473




4GlcNAc-Sp0 705 6887 6014 7 11 7 18 2733 711
305 Galb1-4GlcNAca1-6Galb1-4GlcNAcb-Sp0 670 3818 522 23 27 854 2 498 116
143 Galb1-3GalNAcb-Sp8 638 1384 7532 13 16 240 867 938 2103




Sp14 539 2450 1077 16 17 2 3 200 407




3)GalNAca-Sp8 377 6312 672 22 11 20 23 416 140
539 Galb1-3GalNAcb1-3Gal-Sp21 362 675 14660 13 9 357 716 1627 2030
298 (6S)Galb1-4(6S)GlcNAcb-Sp0 357 178 17 1031 1007 371 0 28 10







Sp0 305 5042 4116 7 9 12 1 1455 541
147 Galb1-3Galb-Sp8 282 3381 775 15 8 19 4 999 334









6)GlcNAc-Sp21 254 5460 701 -1 11 8 8 363 201
134 GlcNAcb1-6(Galb1-3)GalNAca-Sp8 251 2325 2433 23 21 25 41 487 315




4GlcNAcb-Sp8 181 455 57 2 3 652 -1 25 21
132 Galb1-4GlcNAcb1-6GalNAca-Sp8 180 246 286 15 7 -1 33 25 45




















Sp14 136 1479 1131 25 17 13 16 90 178



































Sp0 125 5393 3652 2 3 11 5 2273 462
195 GlcNAcb1-6Galb1-4GlcNAcb-Sp8 101 110 64 8 6 21 132 53 18




Sp14 89 11 60 7 6 5 4 26 29









3)GalNAc-Sp14 85 2418 280 8 17 4 5 48 59
171 Galb1-4GlcNAcb-Sp23 85 370 44 10 25 6 -1 24 17
14 Manb-Sp8 84 106 80 25 13 3 15 35 59
156 Galb1-4(6S)Glcb-Sp0 81 329 25 19 17 9 3 16 10
173 Galb1-4Glcb-Sp8 81 58 49 7 15 9 0 18 7
22 6S(3S)Galb1-4(6S)GlcNAcb-Sp0 79 48 12 77 52 13 1 24 28
165 Galb1-4GlcNAcb1-3Galb1-4Glcb-Sp0 74 545 30 7 10 3 6 25 15
110 Gala1-4(Gala1-3)Galb1-4GlcNAcb-Sp8 70 4075 71 63 24 17 9 609 65



































Sp24 66 3529 253 13 32 18 10 203 57



























3)GalNAca-Sp14 57 844 526 11 21 9 7 41 76
24 (3S)Galb1-4(Fuca1-3)(6S)Glc-Sp0 55 53 33 43 29 2 13 18 25




































Sp24 51 3837 354 10 69 16 14 611 45























4GlcNAcb-Sp24 46 4102 251 9 37 2 -3 492 29

















Sp24 45 393 82 9 22 7 10 59 32
















Sp24 44 3293 200 19 37 11 17 511 48
441 Galb1-6Galb-Sp10 44 908 37 9 15 21 3 252 11
511 Galb1-3(6S)GlcNAcb-Sp8 42 339 50 0 6 16 -2 30 10
109 Gala1-3(Fuca1-2)Galb-Sp18 41 861 41 67 26 3 26 50 48






































3)GlcNAcb-Sp0 37 40 37 14 10 16 8 42 32
12 Galb-Sp8 37 795 36 28 21 10 16 230 26




Sp14 36 134 46 14 13 6 8 32 25




























Sp21 34 3595 186 7 17 9 4 139 36
62 Fuca1-2Galb1-3GalNAca-Sp8 34 23 13 4 6 3 3 9 7
17 GlcNAcb-Sp8 33 26 10 9 29 6 1 32 23
85 (3S)Galb1-4(Fuca1-3)Glcb-Sp0 33 11 24 8 8 16 3 9 11



























3Galb1-4GlcNAcb-Sp0 31 718 44 0 11 2 6 26 19





3)GalNAc-Sp14 31 31 36 20 14 5 15 30 21
31 (3S)Galb1-3GlcNAcb-Sp8 31 53 44 26 13 9 4 40 32
445 (6S)Galb1-3(6S)GlcNAc-Sp0 30 71 21 110 126 175 2 27 7
233 GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp8 30 19 14 0 2 -1 4 13 11






























3GalNAca-Sp14 29 152 50 22 18 17 6 49 47


































4GlcNAc-Sp21 28 1760 227 2 9 8 5 94 30
7 Fuca-Sp9 28 351 150 20 16 4 6 164 169






















Sp0 26 73 20 3 6 6 -2 18 12
5 GalNAca-Sp15 26 52 33 16 20 7 6 18 19
10 Neu5Aca-Sp11 25 29 19 7 9 13 0 13 10


























3)GalNAca-Sp14 24 227 46 13 31 19 14 38 38






4GlcNAcb-Sp19 24 3977 25 14 9 2 0 100 16






















Sp24 23 20 17 3 22 10 9 19 16
99 GalNAcb1-4GlcNAcb-Sp0 23 53 37 30 39 6 4 53 44
13 Glcb-Sp8 23 30 29 6 29 13 7 23 27









4GlcNAcb-Sp25 23 29 29 13 3 11 0 16 15




Sp14 23 68 28 10 13 11 -1 25 25
63 Fuca1-2Galb1-3GalNAca-Sp14 23 53 47 9 14 9 6 10 20







4GlcNAc-Sp19 22 414 17 7 14 3 2 49 18















Sp14 22 32 31 7 7 14 2 20 14









































4GlcNAcb-Sp12 21 404 60 5 15 16 3 28 33



















4GlcNAcb-Sp12 20 9 5 7 13 12 3 16 6




Sp0 20 179 28 7 7 10 5 68 33




































3)GlcNAc-Sp8 19 22 26 23 14 15 2 18 9
260 Neu5Aca2-3Galb1-4GlcNAcb-Sp0 19 11 5 6 16 2 2 10 18
126 Galb1-2Galb-Sp8 19 4722 31 10 20 21 2 1136 10
314 Mana1-6Manb-Sp10 19 19 11 8 -5 2 2 17 24
221 Fuca1-2(6S)Galb1-4GlcNAcb-Sp0 19 13 14 26 35 16 3 13 14
38 (3S)Galb-Sp8 19 24 23 2 7 6 1 15 22












Sp14 19 134 1723 6 14 4 12 111 155






3)GlcNAcb-Sp0 19 74 19 2 27 3 3 13 11











4GlcNAcb-Sp12 18 49 24 20 30 25 23 33 21
120 Gala1-4(Fuca1-2)Galb1-4GlcNAcb-Sp8 18 1743 87 29 27 16 10 2179 24




4Glcb-Sp0 18 15 9 13 2 8 2 6 5





3)GalNAca-Sp14 18 717 400 5 17 9 6 26 86



















Sp19 17 101 18 14 11 10 3 19 26
493 (3S)Galb1-3(Fuca1-4)GlcNAcb-Sp0 17 8 22 9 4 5 8 6 19




















































2)Galb1-4GlcNAcb-Sp0 17 432 142 10 6 6 4 39 41
291 Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp0 17 15 13 9 7 18 10 21 17















































3Galb1-4GlcNAcb-Sp8 16 40 27 13 14 17 9 31 14










4GlcNAcb-Sp20 16 4 8 21 10 12 5 11 16
502 Fuca1-2(6S)Galb1-3(6S)GlcNAcb-Sp0 16 35 24 11 17 35 2 43 19










Sp12 16 62 20 9 6 12 5 23 15
323 Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 16 3 15 13 4 6 3 9 8










Sp24 16 26 14 13 20 12 3 15 13








6)GlcNAcb-Sp22 16 80 11 10 9 18 0 12 11

























4GlcNAc-Sp0 15 1066 38 7 16 24 0 50 16
329 Neu5,9Ac2a2-3Galb1-4GlcNAcb-Sp0 15 15 5 5 7 13 -2 12 15
273 Neu5Aca2-6Galb1-4Glcb-Sp0 15 10 2 5 37 8 -1 7 7
107 Gala1-3(Fuca1-2)Galb1-4Glcb-Sp0 15 672 25 19 14 5 -1 47 18






4GlcNAcb-Sp12 15 14 3 0 10 2 1 18 18









3)Galb1-4Glc-Sp21 15 91 10 8 22 9 -1 15 7
152 Galb1-4(Fuca1-3)GlcNAcb-Sp0 15 119 15 8 9 10 2 18 12





2Mana1-3)Mana-Sp9 15 13 18 6 14 7 1 15 6











3Galb1-4Glcb-Sp0 15 25 14 13 14 7 3 15 6







3GalNAca-Sp14 15 16 6 6 14 6 -1 21 15






Sp0 15 628 53 7 7 9 -2 36 17
95 GalNAcb1-3GalNAca-Sp8 14 7 4 2 3 4 2 18 7
307 GalNAcb1-3Galb-Sp8 14 5 6 4 15 11 1 3 15



















4GlcNAcb-Sp19 14 1146 25 3 20 33 4 57 13




3)Mana-Sp9 14 14 8 4 10 1 1 9 14
194 GlcNAcb1-6GalNAca-Sp14 14 7 11 8 3 4 5 15 19
224 Neu5Aca2-3Galb1-3GalNAca-Sp8 14 23 19 11 4 11 4 16 12



















Sp24 14 41 18 15 23 7 5 14 17






4Glcb-Sp0 14 131 31 11 21 16 8 33 18





3)Galb1-4Glc-Sp21 14 80 36 12 17 2 1 14 18









4GlcNAcb-Sp0 14 8 15 2 16 4 0 9 4
515 GalNAcb1-4(6S)GlcNAc-Sp8 14 18 21 3 7 7 4 8 12




















4GlcNAcb-Sp12 13 12 17 10 15 4 4 5 6




Sp14 13 50 25 6 25 13 3 11 2
98 GalNAcb1-4(Fuca1-3)GlcNAcb-Sp0 13 68 25 31 33 14 17 40 30
410 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb-Sp21 13 18 12 4 7 4 5 2 14




4Glcb-Sp10 13 9 9 4 10 9 -1 11 9
























4GlcNAcb-Sp19 13 28 14 2 11 11 4 22 16





























4Galb1-4Glcb-Sp9 13 16 15 6 1 7 2 20 7







4GlcNAcb-Sp25 13 13 6 17 14 10 2 15 16
207 KDNa2-3Galb1-4GlcNAcb-Sp0 13 14 10 6 11 5 5 6 12











Sp12 12 43 27 4 12 13 -1 3 9





Sp0 12 20 9 7 15 3 0 10 4






Sp19 12 8 7 5 18 13 3 14 9







4Glc-Sp21 12 29 5 8 9 12 3 21 8




449 Galb1-4GlcNAcb1-2Mana-Sp0 12 30 15 8 18 18 5 18 18
150 Galb1-3GlcNAcb-Sp0 12 80 23 14 24 12 -1 9 5
29 (3S)Galb1-3GalNAca-Sp8 12 19 9 9 9 6 2 24 1
























4GlcNAcb1-Sp8 12 13 23 15 5 9 0 14 2






Sp22 12 85 15 5 27 4 1 29 20





































Sp22 12 221 28 10 19 9 7 23 20
284 Neu5Gca2-3Galb1-4GlcNAcb-Sp0 11 10 6 7 7 11 2 9 12




4Glcb-Sp0 11 12 12 6 10 8 1 7 8
























Sp20 11 480 12 14 12 1 4 21 12
360 KDNa2-3Galb1-3GalNAca-Sp14 11 9 14 5 3 9 0 10 12
237 Neu5Aca2-3GalNAca-Sp8 11 7 5 7 12 7 2 22 15
119 Gala1-3Galb-Sp8 11 3303 10 230 6 2 1 389 8








3)GalNAca-Sp14 11 10 2 9 4 7 1 10 16
124 Gala1-4GlcNAcb-Sp8 11 5034 54 573 8 237 5 1641 36
69 Fuca1-2Galb1-3GlcNAcb-Sp8 11 21 23 7 16 11 0 17 15
33 (3S)Galb1-4(Fuca1-3)GlcNAc-Sp8 11 170 12 9 14 7 2 14 5
500 Fuca1-2Galb1-4GlcNAcb1-2Mana-Sp0 11 11 7 4 6 11 -2 15 13
282 Neu5Gca2-3Galb1-3GlcNAcb-Sp0 11 10 10 7 1 3 -1 9 4










Sp0 11 5 15 -1 3 7 2 10 3
198 Glca1-6Glca1-6Glcb-Sp8 11 14 9 8 -1 11 0 16 17
82 Fucb1-3GlcNAcb-Sp8 11 6 11 12 10 9 -1 14 23
68 Fuca1-2Galb1-3GlcNAcb-Sp0 11 11 18 3 9 12 -6 6 6










Sp14 11 16 12 3 14 4 1 7 38
178 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp14 11 24 14 7 10 -2 4 9 14

















Sp12 11 293 30 3 7 2 2 15 7
86 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp0 10 4 14 3 13 -1 -1 6 9




Sp0 10 28 24 11 11 9 2 17 17



















3)GlcNAcb-Sp0 10 26 25 19 8 3 9 22 29




Sp14 10 5177 13 263 11 5 2 514 11
299 (6P)Glcb-Sp10 10 20 16 13 7 20 1 11 5









4GlcNAcb-Sp12 10 25 25 14 31 7 6 17 17






















Sp20 10 1037 8 12 7 11 4 38 15
444 (6S)Galb1-3GlcNAcb-Sp0 10 32 14 50 21 4 6 21 3






4GlcNAc-Sp21 10 15 10 6 10 6 0 23 42
206 KDNa2-3Galb1-3GlcNAcb-Sp0 10 15 10 5 5 1 -4 6 5





Sp0 10 160 23 8 13 8 6 30 7













4GlcNAcb-Sp12 10 22 14 2 8 7 1 9 9




3GalNAc-Sp14 10 42 18 4 5 8 -1 25 11
39 (6S)(4S)Galb1-4GlcNAcb-Sp0 10 12 7 8 18 3 4 18 10












Sp22 10 9 24 0 2 7 0 4 8

















Sp14 9 22 24 8 5 15 0 14 4









3)Galb1-4Glcb-Sp21 9 19 24 18 10 21 -2 10 15
345 GlcNAca1-4Galb1-3GalNAc-Sp14 9 20 14 -1 11 6 4 13 11




3GlcNAcb-Sp0 9 15 12 9 6 9 8 3 12








6)GlcNAcb-Sp22 9 253 8 8 6 9 3 16 8
223 Fuca1-2(6S)Galb1-4(6S)Glcb-Sp0 9 18 14 5 12 20 -1 21 14







6GalNAc-Sp14 9 6 17 10 12 1 1 14 5
246 Neu5Aca2-3Galb-Sp8 9 19 10 14 13 4 2 13 19












4GlcNAcb-Sp21 9 24 4 4 10 8 1 7 12
571 (3S)GlcAb1-3Galb1-4GlcNAcb1-2Mana-Sp0 9 18 9 5 18 15 1 9 4
48 Neu5,9Ac2a-Sp8 9 19 6 16 11 16 -1 8 6
















4GlcNAcb-Sp19 9 7847 66 10 25 14 4 3705 20
112 Gala1-3GalNAca-Sp16 9 3432 13 0 5 18 -1 864 9
367 Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21 9 13 7 2 6 3 -2 10 8




4GlcNAcb-Sp0 9 8 10 25 9 2 3 13 11
121 Gala1-4Galb1-4GlcNAcb-Sp0 9 4575 56 17 14 15 3 2206 15
275 Neu5Aca2-6Galb-Sp8 9 11 5 11 6 12 -2 11 13






















4GlcNAc-Sp21 8 13 12 6 4 8 -3 3 6





































Sp20 8 1771 16 7 10 7 1 29 5












Sp12 8 9 10 32 16 9 2 7 5
468 Gala1-3(Fuca1-2)Galb1-3GalNAca-Sp8 8 193 7 10 13 8 3 10 6




3)(6S)GlcNAcb-Sp8 8 2 14 10 6 7 -1 6 11










4GlcNAcb-Sp21 8 11 4 14 6 2 0 5 9
222 Fuca1-2Galb1-4(6S)GlcNAcb-Sp8 8 26 25 1 9 17 -2 12 9
249 Fuca1-2(6S)Galb1-4Glcb-Sp0 8 13 5 2 12 10 -1 17 12








3)Mana-Sp9 8 15 7 11 3 -4 1 18 14
210 Mana1-2Mana1-3Mana-Sp9 8 22 17 13 11 10 -1 16 19
357 KDNa2-3Galb1-4(Fuca1-3)GlcNAc-Sp0 8 20 16 13 13 4 9 13 21
130 Galb1-3(Fuca1-4)GlcNAc-Sp8 8 94 24 14 10 4 0 28 18
83 GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb-Sp0 8 11 10 11 10 8 2 17 25
269 Neu5Aca2-6Galb1-4GlcNAcb-Sp0 8 5 20 14 13 7 -1 16 9
122 Gala1-4Galb1-4GlcNAcb-Sp8 8 363 71 4 7 31 4 2083 36








4GlcNAcb-Sp0 8 5 10 18 5 16 2 -1 17
518 Galb1-4(6P)GlcNAcb-Sp0 8 8 14 1 6 6 2 11 9

























4GlcNAcb-Sp12 7 10 7 9 8 6 2 7 6
61 Fuca1-2Galb1-3(Fuca1-4)GlcNAcb-Sp8 7 11 15 9 5 6 2 9 23
250 Neu5Aca2-3Galb1-3GlcNAcb-Sp0 7 25 16 4 18 8 6 15 18
30 (3S)Galb1-3GlcNAcb-Sp0 7 18 9 11 4 8 3 8 16
187 GlcNAcb1-4-MDPLys 7 13 9 11 7 12 1 19 5
251 Neu5Aca2-3Galb1-3GlcNAcb-Sp8 7 5 9 8 15 5 5 9 8






Sp14 7 1336 13 11 8 12 2 52 22















4GlcNAcb-Sp21 7 11 3 12 6 13 0 8 5
503 Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 7 15 27 4 10 12 0 11 21
218 Manb1-4GlcNAcb-Sp0 7 18 16 13 16 23 5 11 22
182 GlcNAcb1-3Galb-Sp8 7 67 9 10 8 0 0 5 18




Sp21 7 4 9 4 8 8 0 11 16
528 Gala1-3Galb1-3GlcNAcb1-2Mana-Sp0 7 5977 21 29 7 4 1 881 12






3)Mana-Sp9 7 13 11 2 9 4 1 11 5
234 GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 7 12 11 13 2 23 5 20 14
311 GlcNAcb1-4GlcNAcb-Sp10 7 4 12 10 5 17 3 14 9










4GlcNAcb-Sp21 7 10 8 4 7 8 2 10 4















4Glcb-Sp0 7 5 6 8 7 6 5 12 14





Sp14 7 19 17 1 7 12 4 15 15








4GlcNAcb-Sp0 7 20 11 6 8 13 -1 11 14








4GlcNAcb-Sp20 7 10 9 11 7 9 -1 16 7





























4GlcNAcb-Sp0 7 13 10 5 23 5 2 17 7
409 GalNAcb1-3Gala1-6Galb1-4Glcb-Sp8 7 5 17 6 9 13 -3 14 9
73 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb-Sp8 7 17 10 3 9 7 -3 13 11








































Sp14 6 11 4 7 15 12 -1 21 23




















3GlcNAcb-Sp0 6 12 9 2 7 9 2 6 10











4Glcb-Sp0 6 3 9 3 12 3 -2 2 3
567 GlcNAb1-3Galb1-3GalNAc-Sp14 6 11 11 1 10 6 0 16 5
239 Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 6 24 29 7 8 14 -3 15 24
288 Neu5Gca-Sp8 6 20 13 7 15 7 -1 19 7
267 Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 6 17 4 2 8 4 -1 13 4
286 Neu5Gca2-6GalNAca-Sp0 6 8 4 3 19 6 2 11 12










3)GlcNAcb-Sp0 6 10 9 2 13 8 -1 8 8
























Sp14 6 10 20 10 20 28 3 16 11
188 GlcNAcb1-6(GlcNAcb1-4)GalNAca-Sp8 6 10 9 4 18 12 -2 4 7
513 (6S)GalNAcb1-4GlcNAc-Sp8 6 23 7 2 10 8 -1 17 13





















Sp14 6 49 19 11 8 3 2 13 9
108 Gala1-3(Fuca1-2)Galb-Sp8 6 803 15 6 10 9 -1 74 5








2)Galb1-4Glcb-Sp0 5 12 14 1 2 4 2 17 8




Sp8 5 121 9 2 9 14 -1 19 8


























5 8 11 17 20 1 1 17 14
177 GlcNAcb1-6(GlcNAcb1-3)GalNAca-Sp8 5 8 15 3 10 4 1 11 10
454 GalNAcb1-4Galb1-4Glcb-Sp0 5 29 13 11 8 14 3 26 18




4Glc-Sp0 5 10 7 13 10 -1 -2 8 34
442 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 5 21 12 3 7 10 0 12 5






Sp12 5 56 10 4 2 1 2 9 16
40 (4S)Galb1-4GlcNAcb-Sp8 5 9 8 3 12 9 -1 17 30





















Sp14 5 9 22 2 23 21 -4 9 3





4GlcNAcb-Sp12 5 18 25 0 12 3 3 13 2



























Sp21 5 228 28 5 9 5 0 14 28












Sp21 5 9 5 11 4 0 -1 5 16
89 GlcNAcb1-3Galb1-3GalNAca-Sp8 5 9 13 5 14 11 1 15 8








4GlcNAcb-Sp0 5 6 14 4 8 14 3 14 9




4GlcNAcb-Sp13 4 30 12 9 9 1 0 9 17













4GlcNAcb-Sp21 4 4 8 8 3 6 2 7 13
103 Gala1-3(Fuca1-2)Galb1-3GlcNAcb-Sp8 4 1036 3 3 5 6 5 43 8






























Sp0 4 16 5 1 6 5 1 29 10













4Glc-Sp21 4 17 8 15 11 23 -1 5 7
236 Neu5Aca2-6(Neu5Aca2-3)GalNAca-Sp8 4 8 4 1 10 16 0 9 5
186 GlcNAcb1-3Galb1-4Glcb-Sp0 4 9 12 0 7 17 -1 9 12





3)GalNAca-Sp14 4 22 19 7 8 9 2 18 8
































3Galb1-4GlcNAc-Sp0 4 13 7 11 7 3 2 10 12
469 Gala1-3(Fuca1-2)Galb1-3GalNAcb-Sp8 3 58 15 15 14 6 -1 22 27









4GlcNAcb-Sp13 3 17 8 7 5 4 1 4 5
90 GalNAca1-3(Fuca1-2)Galb-Sp8 3 8 20 7 13 15 2 7 8
408 Galb1-3GlcNAca1-6Galb1-4GlcNAcb-Sp0 3 56 19 6 6 5 5 10 5






Sp14 3 7 22 18 4 2 -2 10 17
297 4S(3S)Galb1-4GlcNAcb-Sp0 3 11 15 3 12 9 -1 12 9
563 GalNAcb1-3GlcNAcb-Sp0 3 7 18 5 18 9 -1 5 7
199 Glcb1-4Glcb-Sp8 3 20 26 8 23 10 0 22 32

















4GlcNAcb-Sp12 3 7 20 6 6 11 1 7 6
558 Neu5Aca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 3 13 6 4 4 19 -2 7 9
153 Galb1-4(Fuca1-3)GlcNAcb-Sp8 3 108 19 5 9 5 2 19 7
















4GlcNAcb-Sp12 3 10 8 9 1 6 -2 12 3
208 Mana1-2Mana1-2Mana1-3Mana-Sp9 3 14 18 3 4 6 1 20 16








4GlcNAcb-Sp0 2 11 6 8 30 12 2 14 13






























4GlcNAc-Sp12 1 17 13 11 6 3 5 3 5







4GlcNAc-Sp19 1 18 4 7 7 10 3 11 8

















3)Galb1-4Glc-Sp21 0 140 35 8 4 12 2 23 10




Sp8 0 9 4 4 2 5 2 19 7
522 Gala1-3Galb1-4GlcNAcb1-2Mana-Sp0 -1 3731 19 29 7 10 2 915 10
87 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb-Sp8 -2 14 7 6 4 8 3 9 0
279 Neu5Acb2-6GalNAca-Sp8 -7 3 -3 4 7 4 3 12 -7
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Chapter 3      Implications of NAD+ limitation and a BAS1∆ 
3.1 Introduction 
      Proper maintenance of cellular concentrations of nicotinamide 
adenine dinucleotide (NAD+) are critical for a multitude of important 
metabolic and biological processes such as (DNA repair, transcription, 
redox state regulation, Ca2+ stores, apoptosis, stress resistance and 
endocrine signaling) and when imbalances occur they often lead to 
various human diseases or even death as in the case with pellagra; a rare 
occurrence today associated with malnutrition.52 Vitamin B3 
(niacin/nicotinic acid (NA) and its derivatives including the reduced and 
phosphorylated forms (NAD+, NADH, NADP+, and NADPH) are classically 
known as coenzymes that participate and function as hydride acceptors 
and donors in a variety of cellular redox reactions.52–54 In redox 
reactions, the NAD+/NADH and NADP+/NADPH pools are recycled and 
interconverted but overall concentrations are essentially stable. 
Additionally, NAD+ can also act as a substrate that is consumed by NAD+ 
cleaving enzymes such as ADP-ribose transferases, cADP-ribose 
synthases and Sirtuin-type (Type III) protein deacetylases.53 These 
reactions act to decrease the NAD+/NADH pool and require a constant 
resynthesis of NAD+ either by salvage of NAD+ catabolites or through de-
novo synthesis. The Cormack lab has previously shown that sirtuins in 
the yeast pathogen C. glabrata consume and deplete NAD+ reserves and 
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that reduced levels of NAD+ can regulate virulence by rendering the NAD+ 
-dependent Sir2p histone-deacetylase (HDAC) inactive which in turn 
results in transcriptional derepression of some Epa-adhesin (Epa6, Epa7) 
proteins critical for adherence to epithelial cells and for murine urinary 
tract infections (UTI).16  
 
      Some of the many interesting features of the yeast pathogen C. 
glabrata relate to its evolutionary history. Whole genome duplication 
events followed by extensive gene loss (such as the loss of genes 
necessary to catabolize galactose and allantoin) and possible adaptations 
during human host coevolution has rendered it auxotrophic for many 
metabolically important pathways known to exist in its evolutionary 
related yeasts – S. cerevisiae and in the most common human yeast 
pathogen C. albicans.55 This creates a survival imperative to function as 
a commensal and/or as a pathogen for the acquisition of essential 
micronutrients (pyridoxine, thiamine, nicotinic acid).56 While C. glabrata 
and S. cerevisiae are phylogenetically closely related, S. cerevisiae 
remains non-pathogenic and retains its capacity to synthesize NAD+ de 
novo, by contrast, the pathogenic C. glabrata has eliminated the genes 
encoding the kynurenine pathway, rendering it unable to synthesize 
NAD+ de novo, meaning therefore, that environmental limitation for NA in 
C. glabrata leads to cellular NAD+ depletion. Growth limiting experiments 
for other micronutrients such as – pyridoxine and thiamine have shown 
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that only NA limiting results in the specific induction of EPA6.16 Thus, 
the data are consistent with a model in which the NAD+ dependent 
sirtuins lose functionality under NA limiting conditions.57,58 In addition 
to the previously uncovered results on EPA gene expression mediating 
adhesion to epithelial cells, NAD+ limitation also results in an increase in 
virulence in C. glabrata. In animal studies, following delivery of the 
inoculum into the mouse blood stream, fungal burden is subsequently 
assessed 7 days post infection. Infection with NAD+ starved cells results 
in a fungal burden 10-100x greater than seen with cells that are 
harvested in log phase or cells grown until stationary phase conditions. 
Previous work to try and identify and delineate the key regulators and 
signaling pathways involved in the niacin limitation response led to 
experiments using in-house microarrays to obtain an transcript 
expression profile under such NA-limiting (virulent) conditions. The 
results indicate, as expected, that the majority of the genes induced are 
regulated by the sirtuins – Hst1 and Sir2.59 Surprisingly, the effect of 
NAD+ limitation on increased virulence is not mediated by these key 
regulators – i.e. the NAD+-dependent regulators Hst1 or Sir2, since the 
same effect on increasing virulence by limiting NAD+ was seen with hst1∆ 
sir2∆ mutant strains. There must therefore be at least one additional 
signaling pathway responsible for the effect on virulence. These findings 
are the impetus driving the following studies.  
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      To analyze the transcriptional response to NAD+ limitation and 
explore potential pathways important in regulating virulence, we first 
used microarrays to gather a genome-wide response to NAD+ limitation. 
Within the several hundred genes induced by NA limitation, large sets of 
strongly up regulated genes are orthologues of S. cerevisiae genes 
regulated by the transcription factors Bas1 and Bas2. In S. cerevisiae, 
BAS1 and BAS2 regulate several interconnected metabolic pathways, 
including histidine, adenine biosynthesis, THF (tetrahydrofolate) 
metabolism, and phosphate utilization.60–62 We analyzed the 
transcriptional response of the Bas1 and Bas2 regulons in C. glabrata in 
response to NAD+ limitation. Essentially, almost all the genes associated 
with purine biosynthesis and the interconnected pathways are 
transcriptionally activated by NAD+ limitation. As a follow up to these 
initial findings we extended the microarray analysis in the context of 
mutants lacking the bas1 transcription factor. Our results indicate 
compromised expression of key genes representative of the above 
mentioned pathways. We also show that the mutant strain bas1∆ is 
highly avirulent, consistent with the idea of BAS genes being potential 
regulators of the virulence in C. glabrata.  
 
      The BAS1 and BAS2 (basal) genes are recognized as global 
transcriptional regulatory proteins.63 More specifically they were initially 
identified as basal regulators of HIS4 epression.64 In S. cerevisiae there 
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are two control systems for the HIS4 gene: general and basal. General 
control is a global response to amino acid starvation that is mediated by 
the transcription factor Gcn4 (general control non-derepressible).65,66 
Basal control or in the absence of amino acid starvation high basal level 
Gcn4-independent transcription of HIS4 is maintained by the Bas1 and 
Bas2 proteins.67 The extensive homology between S. cerevisiae and C. 
glabrata from phylogenetic studies reveals a high degree of syntenic 
organization which underlies the conservation of a large number of 
regulatory pathways.55 Efficient utilization of cellular nutrients has 
allowed yeast cells to create very sensitive networks that operate at 
various interconnected levels. A sophisticated level of complexity has 
evolved in yeast for the efficient coordination and coregulation of diverse 
metabolic pathways like purine and histidine biosynthesis.60 Here we 
find multiple points of convergence linking these pathways in a 
compelling way that support results from our qRT-PCR and (–NA) 
microarray analysis. A review of S. cerevisiae literature revealed that the 
transcription factors Bas1 and Gcn4 share common substrates and 
intermediates, such as: the genes (ADE3, ADE4, HIS4, HIS7, SHM2)60,68,69 
and the metabolites 10-formyl THF and AICAR – 5’phosphoribosyl-4-
carboxamide-5-aminoimidazole.60,70 Moreover, they both act through the 
same promoter motif 5’ TGAC/GTC 3’ although the flanking ends may 
differ somewhat.68,71,69 Double deletion mutant strains of gcn4∆ and the 
BAS genes show a loss of expression activity under NA limiting 
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conditions that is in keeping with a synergistic or additive effect and 
consistent with the bas1∆ and (bas1 bas2)∆ mutants.  
 
      Our previous studies (Cormack-lab) dealt with the exploitation of 
host nutrient availability leading to NAD+ depletion as a consequence of 
consumption specifically by sirtuin-HDACs resulting in the de-repression 
of sub-telomeric associated EPA adhesin genes. The following work 
addresses yet another aspect of NAD+ limitation strictly relevant to its 
role in redox reactions and C. glabrata hypervirulence. Once exposed to 
limiting concentrations of NA, C. glabrata transitions from a benign 
commensal organism to an opportunistic yeast pathogen. The impact of 
the micronutrient starvation is so profound that normally repressed 
genes when in the presence of Adenine are bypassed, resulting in 
increased flux through the purine biosynthetic pathway including the 
interconnected pathways of histidine and tetrahydrofolate biosynthesis, 
that ends with the generation of AMP and GMP nucleotides. An analysis 
of the pathway affirmed the role of NAD+ as a cofactor in IMP conversion.  
Remarkably, the hypervirulent phenotype observed under limiting NA 
conditions during murine disseminated infection experiments is 
replicated through the use of Mycophenolic acid (MPA), an inhibitor of 
IMP dehydrogenase. At one level we show that the transcriptional 
regulators Bas1 and Gcn4 are indirectly associated with C. glabrata 
virulence. Furthermore, and perhaps more meaningful are the results 
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which suggest that the driving force behind C. glabrata infection may be 
due to a direct impact on GMP production by an inability to convert IMP 
to XMP due to compromised levels of the enzymatic cofactor NAD+ that 
renders inactive the oxidoreductase – IMP Dehydrogenase which 
ultimately leads to an imbalance of nucleotide pools and creates a 
constitutively active loop on central metabolism pathways in an effort to 
return to nucleotide pool homeostasis.  
3.2 Results 
3.2.1 NAD+ limitation regulates transcription independently of HST1 
and SIR2  
      The working model for gene activation by nicotinic acid (NA) via the 
sirtuins goes as follows: during periods of NA limiting environmental 
supply leads to a drop in the cellular NAD+ concentration thereby 
reducing the function of the NAD+ dependent histone deacetylases 
(HDACs) – the Sirtuin family of proteins. This eventually results in 
transcriptional derepression at normally silenced sub-telomeric regions 
particularly Hst1 and Sir2-repressed loci. Previous transcriptional 
profiling work in the Cormack lab determined that the primary sirtuin 
that mediates the transcriptional response of C. glabrata to NAD+ 
limitation is Hst1, a Sir2 yeast homolog. Additionally, Hst1 was shown to 
regulate the TNR1, TNR2 and TNA1 genes encoding various NAD+ 
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precursors transporters.59 Thus surprisingly, in a (hst1,sir2)∆ mutant the 
hyper-colonization phenotype remains intact as evidenced from results in 
a disseminated infection model (data not shown). To extend these earlier 
observations we carried out a set of microarray analysis of the 
(hst1,sir2)∆ strain grown under limiting NAD+ versus replete NAD+ 
conditions the results of which ultimately show the signature set of low-
NAD+ responding genes unperturbed in the mutant (Table 3.1). The 
summarized values (log2 transformed) represent the average fold changes 
for two dye-swapped biological experiments. The blue highlighted 
numbers show the NAD+ dependent transporters as well as Epa6 are 
Hst1, Sir2 regulated. The remaining sets of representative genes in the 
table belong to the three biosynthetic pathways (purine, histidine, one-
carbon metabolism), which have been consistently validated by 
quantitative RT-PCR (Figure 3.1C, Figure 3.2B). Microarray gene 
induction values for ADE1, HIS4, MTD1 and SHM2 between wild type and 
(hst1,sir2)∆ are almost identical and again show similar expression levels 
in qPCR analysis discussed below. Other notable genes not analyzed by 
qPCR: ADE4, ADE8, HIS7, HIS1 also remain responsive to limiting NA, 
apparently independent of Hst1 and Sir2 (Table 3.1). 
 
      One concern with the analysis above is that the NA-limited cells have 
stopped growing, while the NA-replete cells are in mid log phase. We 
wanted to confirm that the induction of the genes from the purine, 
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histidine and THF pathways was due to NA limitation rather than as a 
result of growth inhibition or a difference in cell densities (OD). Since we 
know that limitation for glucose has no effect on virulence in C. glabrata 
(i.e. there is no increase in kidney colonization, as seen with NA 
limitation), we chose to grow C. glabrata under limiting glucose 
conditions as a control. C. glabrata cells in NA replete SC media but with 
limiting glucose (0.04% dextrose) stop growing at the same OD600 as cells 
grown in limiting NA conditions (Figure 3.1A,B). Yeast cells were 
harvested along stationary phase growth for both NA starved and NA 
replete conditions (OD600 1.5). RNA for qRT-PCR analysis was prepared 
as detailed in Materials and Methods. RNAs were normalized to HHT2 
and expression induction ratios were determined. The (hst1 sir2)∆ strain 
shows that TNR1 transcriptional induction was reduced 15-fold and 
transcriptional induction of TNA1 was similarly reduced over 10-fold 
while EPA6 was knocked down 3-fold, when compared to wild type 
expression levels (Figure 3.1C). This is expected as their regulation by 
Hst1 and Sir2 has been thoroughly established. Of significant 
consequence is the fact that our signature set of genes: MTD1, SHM2, 
HIS4 and ADE1 remained responsive with almost identical expression 
ratios compared to wild-type cells grown in limiting NA SC media (Figure 
3.1C). These qPCR results along with mouse infection results where 
(hst1, sir2)∆ remains hypervirulent (data unpublished) give strong 
support to conclude that the low NA virulent signal is mediated 
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independently of the well known NAD+ dependent regulators Hst1 or 
Sir2.57,58  
3.2.2 The BAS transcription factors (Bas1, Bas2) activate 
transcription of target genes in response to limiting NAD+  
      The limiting NA effect is characterized by growth inhibition evidenced 
by 24-hour growth monitoring (Figure 3.2A) of NA (3.25 µM) replete and 
NA (0.01625 µM) starved C. glabrata cells. A subset of genes that are 
highly up regulated in response to low NAD+ levels strikingly belong to 
three distinct biosynthetic pathways. Interestingly, these three pathways 
(purine, histidine, single-carbon metabolism) display cross-pathway 
interdependent regulation.60,61,70 Previous work (Cormack-lab) has found 
that almost every member of each of these pathways appears to be 
strongly induced. These pathways have been extensively studied and are 
known to be under control of the Bas1 and Bas2/Pho2 (basal) global 
transcription factors. Utilizing a series of deletion strains: bas1∆, bas2∆ 
or the (bas1 bas2)∆ mutants we show that the absence of these 
transcription factors appears to attenuate the hyper-colonization 
phenotype as demonstrated by our murine disseminated infection 
experiments (Figure 3.2 C-D). Yeast cells for mouse infection experiments 
were prepared as detailed in Materials and Methods section and colony 
forming units (CFUs) of C. glabrata cells recovered from mouse target 
organs (kidneys) on Pen/Strep plates were assessed 2-days following 
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30ºC incubation. As expected, BG2-wt cell counts for –NA displayed the 
hyper-colonization phenotype resulting in CFUs of over an order of 
magnitude greater than the non-starved (+NA) cells. Surprisingly, the 
bas1∆ mutant grown in limiting NA conditions did not show hyper-
colonization. In fact the CFUs did not simply show avirulence but the 
counts were well below the +NA replete grown cells, almost a whole order 
of magnitude and curiously the bas1∆ +NA CFUs were significantly lower 
than the wild-type +NA CFUs. The bas2∆ mutant showed an intermediate 
effect not as clear or profound as bas1∆ while the (bas1 bas2)∆ 
recapitulates the bas1∆ effect (Figure 3.2C-D). The results suggest that 
Bas1 plays an important role in C. glabrata infection inhibition. 
Nonetheless, a concern arises when considering the +NA control group 
results for all the Bas mutants in both experiments. Even when the bas1 
mutants were not starved, their colonization of organs was lower than 
that seen for wild type cells. This raises the possibility that BAS1 may be 
required for growth in vivo, as opposed to response to the NA depletion 
per se. This possibility prompted us to create a bas1 conditional 
knockout – a description of those experiments and results are discussed 
further below. 
 
      Interestingly, the pre-conditioning of C. glabrata cells in low NA 
media allows the pathogen to overcome the Adenine repression, which 
results in increased activation thru the purine biosynthetic pathways as 
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well as the establishment of a virulent program. We explored the extent 
of the impact of the BAS genes in pathway regulation and C. glabrata 
hyper-virulence in the context of a limiting NA environment. Gene 
expression analysis utilizing representative genes of the three 
biosynthetic pathways was conducted by real-time quantitative reverse 
transcription PCR (qRT-PCR). Yeast cells were harvested simultaneously 
at matching times (5hrs) and OD600 (~0.5) in early log phase for qPCR 
analysis. Our mouse infection results are further supported by the 
expression inhibition of our signature low NAD+ responsive genes – as 
shown in the qPCR results (Figure 3.2B). The extent of NAD+ starvation is 
indirectly shown by the strong induction of the nicotinic acid 
transporters (TNR1, TNA1) while the bas1∆ and bas2∆ mutant strains 
ratios show an almost 10 fold reduction in the level of expression for 
most of our three pathway representative genes tested: MTD1, SHM2, 
ADE1. Notably, the histidine gene (HIS4) is relatively unaffected and 
appears to behave independent of the Bas factors. Although our results 
strongly suggest a role for Bas1 inhibition, we can see that the bas1∆ 
alone fails to activate genes associated with central metabolism; however, 
the result is confounded due to the potential slow growth effect. Others 
have reported a slow growth phenotype for the bas1∆ although this has 
been mainly attributed to the absence of adenine.60,68 We have examined 
bas1∆ growth conditions for multiple bas1∆ isolates (#2521, #2522, 
 119 
#3354) both in SDC and YPD media and have found no slow growth 
effects for the bas1∆ mutant (Figure 3.3 A-B).  
 
      The limiting NAD+ response is not unique to the clinical isolate BG2 
and has also been catalogued for the CBS138 C. glabrata strain (Figure 
3.3C). qPCR analyses also show comparable levels of gene expression as 
seen in the BG2 strain. To help establish a sense of our signature genes 
transcript expression levels we carried out a time course analysis of –NA 
induction across a 24-hour period by qRT-PCR. Expression levels were 
normalized to log phase (OD600 =0.5) +NA cells. On average, peak 
expression level ratios appear to max-out around 8-10 hours (Figure 
3.3D). 
 
      Moreover, the microarray analysis of the bas1∆ strain provides 
compelling evidence that additional factors could be involved in the 
regulation of the interlinked biosynthetic pathways of purine, histidine 
and one-carbon metabolism. C. glabrata cells were grown overnight in 
SDC media and excess NA (10 µM) to an optical density (OD600) of ~ 0.5. 
The following day the culture was re-inoculated into SDC media in the 
presence of 3.25 µM NA and SDC without NA supplementation at a 
starting OD600 of 0.05. Yeast cells were recovered from log phase OD600 ~ 
0.5 and processed for RNA extraction and preparation to be used in 
microarray analysis. Table 3.2 summarizes a list of genes representing 
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the three up-regulated biosynthetic pathways discussed earlier. Shown is 
a summary of log2-transformed values representing the average fold 
changes for two microarray experiments. During +NA replete conditions 
most genes were not affected by the bas1∆; as expected. One gene did 
stand out with high basal level expression, namely MTD1. When 
analyzing the mutant effect under induced (-NA) conditions most of the 
genes failed to be expressed, again as expected, except for several of the 
HIS regulon members, indicating possible Bas1 independent activation. 
The BG2 wild type induced up-regulation of our listed genes was similar, 
reproducible and consistent with previous data (Cormack-lab). The final 
column of the table illustrates the induction capacity (-NA vs. +NA) of the 
bas1∆ mutant. Surprisingly, about half of the genes appear to be 
compromised for expression while the other half show variable up-
regulated expression levels. Unexpectedly, the bas1∆ strain indicates 
residual activity, from MTD1 and glaringly, the entire Histidine regulon 
(Table 3.2, blue highlighted values). Here, we show that the persistent 
activation of these genes might be ascribed to the presence some 
alternate factor (Bas1-independent). The induced genes from the bas1∆ 
array showed high-level expression that is comparable to results seen in 
BG2 – wild type. Many of the genes showed compromised activation 
levels while the activation of the entire HIS regulon and MTD1 prompted 
closer investigation eventually leading to a cursory review of the 
literature that confirmed the participation of Gcn4 in all three 
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biosynthetic pathways (histidine, purine, 10-formyl THF 
metabolism).62,64,69 Gcn4 is well know to be responsible for HIS4 
activation. These results are in keeping with published literature and 
conclude that Bas1 clearly plays a key role in the regulation of these 
pathways in the context of low [NAD+] as well as in hyper-virulence to 
some extent. A Gcn4 role if any, in C. glabrata colonization remains to be 
established.  
3.2.3 Gcn4 works additively with Bas1 to activate transcription in 
response to limiting NAD+ 
      Interestingly, Gcn4 and Bas1 share and bind independently to the 
same DNA responsive motif (TGACTC).68,69 Gcn4 is a very well known 
global transcription factor that becomes translationally responsive under 
various stressful conditions such as amino acid deprivation.65 Apart from 
its involvement in histidine biosynthesis, previous studies have shown 
that Gcn4 is also necessary for optimal expression of several purine 
genes (e.g. ADE3, ADE4). Our microarray data indicated the presence of 
additional regulatory factors acting in response to the limiting NA 
condition. Consequently, we created a set of gcn4∆ strains along with 
bas1∆ to explore the role of this factor during low NA exposure in C. 
glabrata. Preliminary work on the growth phenotype of the various 
deletion strains indicated the need for supplementation by Tryptophan in 
SC media (Figure 3.4). C. glabrata yeast cells were grown overnight in SC 
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+30 µM excess NA, then inoculated into SD CAA media. Growth curves of 
strains grown in casamino acid (CAA) media showed that a slow growth 
effect in Gcn4 mutants could be overcome by Tryptophan addition. 
Similarly, an extended lag phase for Bas deletions was eliminated by the 
addition of Adenine in SD CAA media.  
 
      Our data from qRT-PCRs of the gcn4∆ double knockout mutants 
uncovered an increased loss of activation for all of our three pathways 
representative genes in conjunction with the bas1∆ and bas2∆ deletions 
but no effect was observed for the gcn4∆ mutant alone. Yeast cells were 
harvested after 12hrs of NA starvation in SC +Ade, +Trp media versus log 
phase cells harvested at 6hrs in replete (+3.25 µM NA) SC media +Ade, 
+Trp. RNA was prepared for qPCR analysis as detailed in Materials and 
Methods. The RNAs from three separate biological experiments were 
normalized to HHT2 and the averaged values were used to determine the 
induced gene expression ratios. For all genes tested: MTD1, SHM2, HIS4, 
ADE1 there is a dramatic reduction in expression levels compared to 
BG2-wild type and a greater than 10-fold reduction of expression 
compared to the single bas1∆ gene deletion mutant. This additive effect 
raises the possibility that Bas1 and Gcn4 may function cooperatively 
under the stressful condition of NAD+ starvation (Figure 3.5 A). Here, we 
show that Gcn4 alone does not have an apparent effect on the expression 
of our limited-NA responsive genes, the effect is present only with 
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double-deletions of the BAS genes that we see complete reduction of gene 
activity ranging from 50-100 fold loss of expression. Whether Bas1 or 
Bas2, and Gcn4 are able to form heterodimeric complexes has not been 
observed experimentally nor did we attempt to address this potential 
scenario. To provide further evidence of the (gcn4, bas1/2)∆ additive 
repressive effects we also performed qPCR analysis from OD matched 
yeast cells grown in SC +(3.25µM NA) and limiting glucose (0.04% 
dextrose) and recovered strains along early stationary phase grown in the 
absence of NA (Figure 3.5 B). This approach adds further evidence that 
the effect is strictly due to NAD+ status and not to a growth phase 
difference, i.e. cell density (OD) changes. Similar results were observed.   
 
      Considering the suppressed transcripts results for the three 
biosynthetic pathways we looked to address the possibility that a Gcn4 
mutant might attenuate the hyper-virulent program of C. glabrata much 
like has been observed by Bas1. Consequently, we performed murine 
disseminated infection experiments to assess the role of Gcn4. Yeast cells 
were prepared as described in Material and Methods and colony forming 
units (CFUs) were recorded from YPD (Pen/Strep) plates. After two 
experiments attempted, our results concluded that gcn4∆ does not affect 
C. glabrata hyper-colonization (Figure 3.5 C-D), although we have shown 
a convincing effect on gene expression for our purine pathways in 
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response to limiting NA conditions. This effect is strictly due to synergism 
with the BAS genes.    
3.2.4 Bas1 conditional knockout mutant: (Bas1 – AID – flag3) 
      To unravel the possible confounding results of Bas1 virulence 
attenuation due to the slow growth effect of the bas1∆ mutant in a non-
ambiguous manner we implemented a conditional knockout system for 
BAS1. Our strategy makes a single modest assumption. Just as C. 
glabrata cells are pre-conditioned to limiting [NAD+] and yet display a 
hyper-colonizing phenotype days after the initial infection, then a 
temporary “pre-conditioning” of a bas1 deletion strain should also render 
an attenuated avirulent phenotype. To clarify this experiment, C. glabrata 
cells to be used in the infection inoculum are grown in the presence of 
IAA (auxin) to swiftly degrade our target Bas1p. Once yeast cells are 
harvested they are washed 2xPBS before mouse injection. At this time 
any remaining Auxin ought to be beyond negligible allowing for efficient 
recovery of the Bas1p knockout consequently no slow growth effect 
should be evident. For this experiment we used a newly established 
Auxin-based degron system for the rapid depletion of proteins.72 The 
advantage of the system rests on the uniqueness of the auxin compound 
as well as the Transport Inhibitor Response-1 (TIR-1) component that are 
found only in plants and that bear no known homologs in the yeast. The 
strategy of the system is supported by the fact that the SCF (skip, cullen, 
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F-factor) complex is evolutionary conserved and maintained from 
bacteria to humans. Briefly, once a protein of interest has been modified 
with the AID (auxin inducible degron) tag, auxin (IAA-indole-3-acetic 
acid) is added to your culture at the desired time where it promotes the 
interaction between TIR1 and the target protein as depicted in the 
schematic (Figure 3.6). Then SCF-TIR1 becomes active as an E3 
ubiquitin ligase that eventually results in the poly-ubiquitination of the 
AID-degron leading to targeted clearance by the ubiquitin-proteasome 
pathway.   
 
      Prior to testing the Bas1 conditional knockout in mouse experiments, 
we performed a series of in-vitro tests of the (Bas1 – AID – flag3) construct 
to ensure appropriate function and predictability of the AID system. It is 
worth mentioning some unsuccessful work regarding the initial design of 
this construct that placed a 3x Flag tag immediately after the BAS1 ORF 
followed by the AID degron. This in fact results in an unstable, 
inoperative Bas1 protein. A redesign of the system places the 
3xMiniDegron (219 amino acid - AID) in frame to BAS1 at the C-terminal 
genomic locus linked to a 3x – Flag tag for detection and a final Stop 
codon in the parental strain BG14 (URA=). An unexposed AID tag is 
essential for proper system implementation. The oligos used in this 
cloning can be found in Table 3.3 and a description in the Material and 
Methods section. The fully functional AID system also contains the TIR1 
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component protein expressed in the pGrb2.3 URA+ plasmid. The Bas1-
AID-flag3 (#BG3857) strain was tested for the low growth phenotype 
observed when wild type strains are cultured in SC media –NA and for 
functionality regarding gene induction of our set of representative –NA 
responsive genes. The Bas1-AID-flag3 strain showed a similar growth 
arrest response as the BG2-wild type when monitored in SC media 
without NA supplementation (Figure 3.7 A). Bas1-AID-flag3 (BG3857), 
appears to function normally as similar activation levels for our signature 
set of –NA responsive genes in BG2-wild type -NA, were duplicated with 
at least 10-fold induction levels obtained in qRT-PCR results (Figure 3.7 
B). Quantitative RT-PCR was also implemented to determine the 
transcriptional response or the loss of activation for a chosen number of 
genes when the conditional mutant system was fully tested with the 
addition of auxin. Yeast cells were grown overnight to log phase and then 
re-inoculated to an OD density of 0.025 in the presence or absence of 
NA. Auxin (IAA – 500 µM) was also added at this time to the –NA cells 
until they were harvested at 12 hours of NA starvation versus log phase 
(OD= 0.5) +NA cells. The qRT-PCR analysis reveals that there is a bas1-
knockout effect for the genes tested: SHM2 and ADE1 (Figure 3.7 C-D). 
Although not very impressive there is a clear difference between the 
auxin+ versus the auxin- transcript level samples. We included some 
additional controls to guard against any possible influence that SDC –
URA media might have on expression due to the parental strain BG 430. 
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Our results indicate that the Bas1-AID-Flag3 +TIR1 +Auxin experiment 
mirrors the bas1∆ effect displayed by the loss of gene activation.   
 
      Additional tests were conducted for the BAS1 conditional knockout. 
A growth curve test was made to determine if we could observe the same 
behavior of a bas1∆ extended lag phase when cells are grown in –Adenine 
conditions. Results of the growth curve (Figure 3.8A) show the knockout 
strain (BG3859 +IAA) directly overlaid onto a bas1∆ when Auxin (500 µM) 
is added to SDC media. More convincingly is the Western analysis of 
Bas1-AID-flag3. Here we show that the AID system is extremely efficient 
and sensitive as a time course degradation analysis was carried out 
whereby samples were recovered at various times during auxin 
treatment: 20min, 40min, 1hr, 2hr and 4hours (Figure 3.8 B). Cell 
lysates were prepared for all three samples (BG3857, BG3859 +IAA, 
BG3859 –IAA) and 40 µg were run on 12% gradient PAGE denaturing 
gels for one hour. Subsequently, the gel was transferred onto a PVDF 
membrane and the Western blot was probed with an anti-Flag ab (1:2 K 
dilution, 2º 1:10 K dilution). The Bas1p is completely degraded by our 
earliest time point 20 minutes and is maintained at least through 4 
hours. One final test checked for the stability of Bas1- AID – flag 
construct by growing the strain in the absence of Adenine. Three 
different Bas-AID-flag conditional strain isolates were analyzed and only 
the bas1∆ displayed an extended lag phase phenotype when grown in SC 
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–Ade (Figure 3.8C) suggestive of tight control over Bas1 degradation. We 
concluded that the AID system was stable and operational for Bas1p. 
Surprisingly, our murine disseminated infection experiment for the 
conditional knockout of Bas1p yielded a perfectly confounding result. 
The BG2 wild type behaved accordingly including a control +NA grown to 
low OD600 in limiting glucose (0.01% dextrose). The unexpected CFU 
counts for the Bas1-AID TIR1 strain approached –NA wild type levels 
(Figure 3.8 D). Moreover, the negative control with an empty pGrb2.3 
plasmid and no TIR1 component shows very similar CFUs result that 
resembles the complete Bas1-knockout system. The results from the 
data imply that the effect at the micronutrient level is not mediated 
through Bas1 during the starvation phase. Assuming that the system did 
work then Bas1p was quickly restored and the cells were able to recover 
fully. Alternatively, considering that Bas1p is constitutively bound to 
DNA and is not up regulated during limiting NA exposure it is possible 
that the protein could be masked in a DNA/promoter complex that 
allows for some brief residual functionality; enough to activate our 
signature set of genes. Adding auxin earlier in the growth phase is not 
practical since that would likely introduce the slow growth effect we are 
directly trying to bypass.    
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3.2.5 IMPDH inhibition mimics the effect of limiting NAD+ in C. 
glabrata 
      Noticing how responsive the central metabolism pathways are to the 
starvation condition of low [NAD+] we investigated the possibility that 
there might be a direct link with NAD+ along one of the three pathways 
that are strongly up regulated. Inspection of these pathways reveals in 
fact, NAD+ does impinge at the branchpoint conversion of inosinate (IMP); 
the GMP arm of purine biosynthesis. NAD+ functions as a coenzyme in 
the conversion of IMP to xanthylate (XMP) that eventually leads to GMP 
generation. NAD+ is the cofactor that impacts the enzyme IMP-
Dehydrogenase (IMPD). This is critically important since excess AMP 
production has no way of being converted back into GMP. Interestingly, 
Mycophenolic acid (MPA) is a drug that specifically inhibits GTP 
synthesis and is widely used to achieve immunosuppression as a 
strategy to prevent allograft rejection.73 Our working premise is that the 
absence of NAD+ leads to a block of GMP/GTP synthesis leading to the 
activation of the pathways as a way to restore and increase the end 
products yielding GMP/GTP. A similar scenario has been shown in S. 
cerevisiae with mutants along the second half of purine biosynthesis 
where deletions that block anywhere downstream of the point of 
synthesis for the metabolites SAICAR or AICAR leads to constitutive 
activation of the pathway while mutants blocking the first part of the 
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pathway leads to adenine auxotrophy.74,75 Presumably, inhibition of 
IMPD should result in a feed forward loop for the purine biosynthetic 
pathway.    
 
      Analyzing the transcriptional readout of MPA blocked cells through 
qRT-PCR was the first test of the hypothesis. Some preliminary 
optimization tests were carried out to help determine an appropriate level 
of [MPA] for our analyses. A working concentration of 25 µg/mL [MPA] 
was added to BG2 log phase cells (OD600= 0.5) resulting in a 
compromised growth phenotype similar to what is observed with –NA 
[≤0.025 µM], (Figure 3.9 A), although the cells eventually do mostly 
recover. We then determined the extent of gene activation by harvesting 
cells at two different time points (4hrs and 7hrs) post MPA introduction 
(Figure 3.9 B). We examined our usual cohort of genes and found an 
average 10-fold expression level difference that is similar to induction 
levels obtained during limiting NA conditions. This data suggests that 
MPA inhibition of IMPD mimics NAD+ starvation and leads to an increase 
in purine pathway activity. Conversely, if a block in GMP/GTP generation 
results in our signature genes being up regulated then the activation 
should be relieved by an excess of guanine supplementation in the 
growth media. Physiological levels of guanine are typically 0.15 mM G; 
we tested two different concentrations of guanine (G): 0.3 mM G and 0.9 
mM G. As expected the compromised growth phenotype was eliminated 
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at both concentrations even when using MPA at 50 µg/mL (Figure 3.9 C). 
A similar analysis was conducted for our pathways representative genes. 
Expression was measured by qPCR and the results were in keeping with 
the growth curve observation. Gene activation was induced by IMPD 
inhibition and substantially reduced by the presence of guanine at both 
0.3 mM G and 0.9 mM G concentrations almost in a linear fashion – 
expression levels were down to approximate basal level transcription 
(Figure 3.9 D). All the genes tested: MTD1, SHM2, ADE1, ADE3, ADE4 
and HIS4 were demonstrably suppressed in their activation. Curiously, 
the TNR1 transporter control was also down although this is truly 
inconsequential considering that under limiting NA, its typical gene 
activation ranges between 100-1000 fold when measured by qPCR. These 
results indicate that the MPA block can be overcome by supplementing 
with guanine. In light of these results it is tempting to consider that the 
limiting NAD+ response can potentially be suppressed by excess addition 
of guanine. We made several attempts to address this possibility but 
were unsuccessful. It is also worth noting that our experiments to 
introduce guanine into cells were not trivial. Guanine presents a 
difficulty of solubilization. It requires manipulations that range from high 
pH (1N NaOH) down to acidic levels for SC media. It is possible that these 
earlier attempts need to be revisited with an improved guanine 
availability protocol. Alternative plausible explanations for the failure of 
excess guanine to cover the limiting NA phenotype may simply lie with 
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the extent of action of the micronutrient (vitamin B3). NAD+ plays a 
major role in a number of different critical pathways that possibly have 
not yet been uncovered in the pathogenesis of C. glabrata. 
 
      The second test of our hypothesis, described earlier, is to assess the 
ability of MPA treated C. glabrata cells to adopt a hyper-virulent program 
leading to hyper-colonization in a manner similar to what is observed 
during limiting NA preconditioning exposure. To that end, we carried out 
a murine disseminated infection experiment to explore the possibility of 
IMPD inhibition mimicking the low [NAD+] response (Figure 3.10). 
Remarkably, our results confirmed the hyper-colonization phenotype by 
MPA inhibition (50 µg/mL). Taken together, our latest data suggests that 
the driving factor behind NAD+ starvation is the creation of a nucleotide 
imbalance between AMP and GMP ultimately resulting in the 
pathogenesis of C. glabrata.  
3.3 Discussion 
      C. glabrata presents a growing public health issue within infectious 
diseases. It has been generally recognized as a human commensal but 
more recently has emerged as an opportunistic pathogen.2 C. glabrata 
shares a common ancestor with S. cerevisiae. Between the two, there 
exists a small number of genetic differences yet through a series of 
acquired attributes, (e.g. variable adherence capacity, drug resistance, 
 133 
starvation resistance, high stress tolerance) have enabled this species to 
survive and thrive in a hostile environment.56,76 The decision whether to 
undertake a commensal or pathogenic lifestyle is not defined by its 
auxotrophies, yet it has evolved to make use of one (nicotinic acid - NA) 
as part of a hyper-virulent program. Results from our findings indicate 
that the pathogenic state of C. glabrata is directly tied to central 
metabolism and that disruption along the 2nd half of the purine de novo 
biosynthesis pathway at points downstream of where the metabolites 
AICAR and SAICAR are generated can lead to a hyper-virulent 
phenotype. We now have two approaches that elicit the same observed 
phenotype; exposure to an NA limiting environment and inhibition of 
nucleotide synthesis (GMP). This is currently an overstatement since it 
remains to be seen whether inhibition of every point along the pathway 
will yield the same results. Nonetheless, the data provides encouraging 
results that warrant the pursuit of this line of questioning. Can the end 
products of purine biosynthesis AMP and GMP overcome the NAD+ 
limiting phenotype? Will constitutively active flux through the pathway 
such as the use of a bas1-bas2 fusion heterodimer complex mimic the –
NA hyper-colonization result? Can the overexpression of any single 
member of the Adenine regulon result in C. glabrata pathogenesis or is 
the hypervirulent program much more complex beyond the purine 
biosynthetic pathway? Does the imbalance of nucleotide pools somehow 
link up with a mechanism that indirectly allows for the derepression of 
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EPA adhesins? Our results here provide a starting point for addressing 
the downstream events following NAD+ limiting exposure.   
 
      We have utilized a set of deletion strains (bas1∆, bas2∆, (bas1 
bas2)∆, gcn4∆, (gcn4 bas1)∆, (gcn4 bas2)∆) to better characterize and 
delineate key factors or pathways responsive to the NA limiting virulent 
signal. We began our analysis with an effort to try and extend the initial 
findings of a (hst1 sir2)∆ mutant that does not play a role in the NA 
limiting phenotype. These are very well known HDACs that are 
functionally dependent on NAD+. Unpublished murine disseminated 
infection experiments showed that the hyper-colonization result was 
persistent in the sirtuin deletion strains. Therefore, we conducted a 
microarray analysis of the (hst1 sir2)∆ to potentially uncover genes 
responsive to the NA limiting signal. Again the data revealed the same 
sets of genes being up regulated, thereby highlighting and emphasizing 
the importance of these pathways in C. glabrata pathogenesis, namely: 
histidine biosynthesis, purine biosynthesis and 10-Formyl 
tetrahydrofolate metabolism. There still remains a possibility for 
alternate drivers within this set of up regulated genes that remain 
unidentified. For example, there may be other ‘NAD+ consuming’ enzymes 
like polyADP ribosyl-polymerases or ADP ribosyl-transferases involved in 
cellular signaling processes vital for survival yet to be uncovered. 
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However we continued to focus on the regulators of these pathways, in 
particular the BAS genes.   
 
      The BAS genes are recognized as global transcriptional regulators. 
Bas1 is constitutively bound to promoter specific DNA sequences 
(TGACTC) in an inactive state until recruitment of Bas2. Conversely, 
Bas2 is not bound to any Bas2 specific DNA elements until it 
heterodimerizes and is allowed to transcriptionally activate genes in 
concert with Bas1. There are a number of studies describing the 
activation and regulatory mechanism of Adenine dependent genes by Bas 
transcription factors. Typically adenine exerts an inhibitory influence on 
the Bas1 – Bas2 interaction either directly or with components of the 
transcriptional machinery that antagonizes the Bas proteins’ activation 
function. It is only when Adenine is removed that we see increased 
accumulation of the purine pathway metabolites SAICAR and AICAR that 
release of the repressive state is achieved and the Adenine regulon is 
allowed to be expressed. Our results show that despite the presence of 
Adenine, exposure to very limiting concentrations of NA, will allow this 
repressive state to be overcome quite readily. Interestingly, various 
studies have shown that Bas1 – Bas2 complex formation is not due to 
expression level changes of either protein or by nuclear exclusion nor a 
repressive factor but rather a masking effect of activation domains for 
both proteins that somehow involves adenine. All of our SC media 
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experiments were conducted with excess adenine (150 µM) indicating 
that this inhibitory effect is overcome by an alternate positive unmasking 
effect on the Bas1 and Bas2 proteins. This unmasking event occurs 
presumably by a generally accepted mechanism by which gradual 
accumulation of the metabolites SAICAR and AICAR provide the 
activation signal for Bas 1/2 transcription factor activation, although a 
physical interaction is yet to be demonstrated.  
 
      A recent series of transcriptome analysis studies of conditions 
leading to GDP or GTP depletion revealed that the great majority of the 
genes (71) affected at least 2-fold were under the control of the Gcn4 
transcription factor.73 Hence, it was somewhat surprising that our gcn4∆ 
mutant was unable to repress the activation of our set of signature genes 
that we see up regulated when guanine nucleotide generation is inhibited 
by MPA. Although it (gcn4∆) did further repress the expression of these 
transcripts in double mutant strains with either of the Bas transcription 
factors, the gcn4∆ single mutant was not able to attenuate hyper-
virulence in our murine disseminated infection model as demonstrated 
by the bas1∆. We have thus shown that Bas1 tightly coordinates the 
regulation of these pathways in the context of limiting NA conditions 
even more so than Gcn4. Knowing the involvement of Gcn4 in limiting 
guanine and in purine biosynthesis it is speculative to consider the 
Gcn4/TOR (target of rapamycin) pathway in mediating the hyper-virulent 
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phenotype. One possible scenario that can be proposed follows AICAR 
accumulation activation of AMPK (AMP-activated protein kinase), which 
in turn inhibits TORC1. A more direct approach could involve the small 
GTPase Rheb that positively regulates TORC1 in the GTP-bound state.77 
The potential involvement of TOR is consistent with its role as an energy 
and nutrient sensor that coordinates anabolic processes and cell cycle 
progression.  
 
      The failure of our Bas1 conditional knockout likely needs to be 
revisited with some fine-tuning of the initial conditions prior to mouse 
infection. Although growth curve tests and protein verifications appeared 
to indicate a positive outcome for the transient ablation of Bas1, it might 
be necessary to maintain auxin in the SC growth media for a much 
longer period of time ahead of transferring the cells into mice. Perhaps 
Bas1 expression necessitates being completely off from the start of 
culture growth until cells are harvested for injection. This should not 
result in a slow growth effect since we have not recorded this (bas1∆) 
effect at least in our tests of liquid cultures.  
 
      Our novel finding shows that the inhibition of IMP-Dehydrogenase 
elicits the same activation of our signature series of up regulated genes 
representing the three biosynthetic pathways similar to the limiting NA 
condition. Equally important is the fact that this gene induction can be 
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blunted or compensated for, by an excess of guanine supplementation. 
The inability to convert IMP to GMP also results in hyper-colonization 
that mimics the previously observed NA limiting phenotype. The key to 
linking NAD+ and GMP would be to see if the –NA response can be 
abrogated by exogenous guanine. Several attempts were made with 
mixed results therefore it remains to be established if these two 
conditions can be reconciled and complemented.  
 
      Our studies into the virulence mechanisms of C. glabrata 
pathogenesis highlight the importance of the purine biosynthetic 
pathways and may have important physiological implications for human 
health regarding neurological deficits and neuronal maintenance. 
Increased accumulation of SAICAR metabolite derivatives have been 
reported to be involved in neurological abnormalities (mental retardation 
and autistic features).78 Similarly, accumulation of AICAR derivatives 
have been reported to be associated with severe neurological defects.79 
Since low [NAD+] leads to increased flux through the purine pathway and 
ensuing SAICAR/AICAR build-up, it is possible that NAD+ depletion can 
be yet another early surrogate indicator for neurological impairment. 
Reduced levels of [NAD+] in various tissue cell types associated with 
aging are of real concern, since this provides an opportunistic 
environment for the establishment and expansion of C. glabrata 
infections. Recent reports have found that increased NAD+ levels can 
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stimulate PGC1α (peroxisome proliferator-activated receptor gamma-
coactivator 1α) production in the brain.80 This was found in mouse 
models of Alzheimer’s disease, which is associated with reduced levels of 
PGC1α suggesting a protective role for NAD+ while simultaneously 
inhibiting yeast infections. One striking report links NAD+ depletion and 
compromised levels of ATP and GTP with the devastating neurological 
disease Lesch-Nyhan – which presents with degrees of severity for 
delayed motor development, renal failure and/or gout along with a very 
dramatic compulsion of self-mutilation in children.81,82 The condition 
arises due to an aberrant HGPRT (hypoxanthine-guanine 
phosphoribosyltransferase) enzyme, part of the ‘salvage pathway’ for 
converting purine bases to nucleotides. The highest activity of HGPRT is 
found in the brain. In yeast, loss of this gene leads to deregulation of the 
purine de novo pathway.83 Additionally, guanine based purines are 
known to be involved in synaptic transmission through the action of 
GEFs and GAPs (Guanine exchange factors and GTPase activating 
proteins) modulators of heterotrimeric G proteins associated at the 
cellular membrane that regulate many second messenger cascades. 
Other consequences related to guanine depletion may affect energy 
metabolism and modulation of glutamatergic neurotransmission among 
other more familiar roles in gene replication and expression.  
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      It remains to be seen whether the prevention of the final reaction 
products GMP or AMP by disruptions of the pathway downstream of the 
SAICAR and AICAR signals will all lead to a hyper-colonizing phenotype. 
Thus far, we’ve established that inhibition of the conversion of the first 
committed step (IMPD) in GMP synthesis indeed leads to a hyper-virulent 
phenotype. We have also confirmed that this phenotype is typically 
characterized by the activation of three biosynthetic pathways (histidine, 
purine, one-carbon metabolism) whether by MPA or by low [NAD+]. Taken 
together our findings indicate that an imbalance of nucleotide levels of 
NAD+ or GMP impacts several cellular functions (e.g. Redox reactions, 
protein deacetylation - HDACs) and signaling systems (eg. GEFs/GAPs) 
that in C. glabrata convergently result in a pathogenic phenotype. 
Previous work from the Cormack lab established the exploitation of NAD+ 
auxotrophy and the derepression of adhesin proteins. Our current work 
extends these findings to show a direct consequence of NAD+ depletion on 
purine biosynthesis. The loss of GMP generation through the absence of 
the NAD+ cofactor or by IMPD inhibition leads to an imbalance of 
nucleotide pools and a series of potentially unknown downstream effects 
due to [guanine] limitation. In C. glabrata infections this leads to kidney 
hyper-colonization (UTI) and an overall yeast burden. The result is likely 
not only due to a proliferation of the infectious organism but is also 
coupled to a set of survival mechanisms activated by low NAD+ and 
compromised nucleotide levels that result in increased adherence 
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accompanied by an inability of immunological clearance by the human 
host. Implications for nucleotide imbalances in human diseases accords 
continued investigation in yeast as a model organism to study the effects 
of proper maintenance of the nucleotide pools NAD+, GMP, AMP and their 






Figure 3.1 Growth curves of BG2-wt in a range of glucose 
concentrations and (hst1,sir2)∆ mutant analysis.  
A, B. C. glabrata cells of #2781 wild type and #1764 hst1∆,sir2∆ (lab 
stocks) respectively, were grown overnight in SDC +NA media to both log 
phase and stationary phase then diluted to an OD600 of 0.05 and 
inoculated into media containing varying dextrose concentrations (0.01, 
0.02, 0.04, 0.2, and 2%). The results established an OD matched +NA 
control by limiting for glucose.  
C. qRT-PCR Analysis for (hst1,sir2)∆ exposed to –NA conditions. Shown 
are the nicotinic acid transporters (TNR1, TNA1) and representative genes 






























































Figure 3.2 qRT-PCR Expression Analysis for BAS Gene Deletion 
Strains and BAS Mutants in Mouse Disseminated Infections. 
A. Low growth effects under limiting NA conditions in SDC media for 
BG2-wt. B. qRT-PCR results for the inductions of representative genes of 
purine biosynthesis pathways including the NA transporters as controls. 
Cells harvested at log phase. Shown are the averages of three 
experiments that indicate loss of gene expression in the BAS∆ mutant 
strains.  
C and D are the results from two separate mouse infection experiments 
that show BAS1∆ strain appears to have an attenuating effect on C. 
glabrata hyper-virulence. BAS2∆ may have a marginal effect 
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Figure 3.3 BAS1∆ Growth Curves and qRT-PCR analysis of –NA Gene 
Induction.  
A and B. Growth curves for several bas1∆ isolates and strains including 
BG2-wt control. From single colonies, cells (bas1∆: #2521, #2522 
isolate#1 and isolate#2 respectively, bas1∆ nat-cured #3354, BG2 #2781) 
were grown overnight to stationary phase in both YPD and SDC+NA (both 
supplemented with Adenine) then diluted to OD600 of 0.1 for 24hr growth 
monitoring. C. qRT-PCR results of the limiting NA effect of C. glabrata 












































































Figure 3.4 Media Tests for Optimal Growth Conditions of Mutant ∆ 
strains.  
The gcn4∆ strain shows no particular growth phenotype even when 
grown in casamino acid (CAA) media as long as it is supplemented with 
Tryptophan. The remaining BAS∆ strains or combinations with BAS 
mutants display expected slow growth phenotypes in the absence of 
Adenine.  
Strains as ordered in the figure correspond to C. glabrata lab stock #s:  
2781 = BG2- wild type 
2521 = Bas1∆ 
2523 = Bas2∆ 
1947 = (Bas1,Bas2)∆ 
3260 = Gcn4∆ 
3310 = (Gcn4∆,Bas1)∆ 
















































Figure 3.5 GCN4∆ Mutant in Mouse Disseminated Infections and 
qRT-PCR analysis of BAS and GCN4 mutants under –NA conditions.  
qRT-PCRs for the various deletion strains show an additive suppressive 
effect between the BAS∆’s and GCN4∆. A. expression changes comparing 
deeply –NA starved cells to early +NA log phase cells. Panel B shows 
similar results while the +NA cells grown in limiting 0.04% glucose were 
similarly OD matched to –NA starved cells.   
Panels C and D are the results from two separate mouse infection 
experiments showing BAS1∆ having an attenuating effect on hyper-
virulence while the GCN4∆ plays no role in the hyper-colonization. This is 
a second isolate for the bas1∆ mutant showing reproducible and 
















































































strains #2781, 2522 and 3260 respectively. In panel D the +NA cells 







Figure 3.6 Schematic of the AID system and indole-3-acetic acid 
(Auxin). 
Auxin binding to TIR1 promotes the interaction between TIR1 and the 
AID - degron of the target protein. SCF-TIR1 acts as an E3 ubiquitin 
ligase to recruit an E2 ligase resulting in polyubiquitylation of the aid 
degron and targeted destruction by proteasome.  
(An auxin-based degron system for the rapid depletion of proteins in nonplant cells.  






Figure 3.7 Bas1 Conditional Mutant tests with qRT-PCR under –NA 
conditions.  
A. Shows the growth curve for Bas1 – AID – flag3 (#3857) strain grown in 
–NA limiting conditions (SDC+URA). B. qRT-PCR results showing the 
induction of representative pathway genes indicating Bas1 – AID – flag3 
is functional.  
C. Shows the growth curves for BG2 (#2781), Bas1∆(#2521), Bas1-AID-
flag3 TIR1 (#3859). The TIR1 (3859) component is maintained in URA- 
SDC media while Bas1 is degraded in the presence of Auxin (IAA); added 
at the start of culture growth under –NA conditions.  Panel D shows the 



























































loss of Bas1 by IAA and suppression of gene expression that is similar or 
worse than bas1∆ levels.  
Both sets of cells for expression analysis were harvested at 12hrs –NA vs. 







Figure 3.8 Bas1 Conditional Mutant – AID Auxin test in-vitro and 
Mouse Disseminated Infections (UTI). 
A. Growth Curve of the various Bas1 constructs in SC +NA –ADE and SC 
+NA –ADE –URA for the TIR1myc strain: 
#2521 – Bas1 ∆ 
#3859 – Bas1 AID flag, TIR1myc   +IAA 
#3859 – Bas1 AID flag, TIR1myc   -IAA 
Growth curves for BG2 (#403), Bas1∆(#2521), Bas1-AID-flag3 TIR1 










































































































while Bas1 is degraded in the presence of Auxin (IAA); added at the start 
of culture grown under –NA conditions. 
B. Western analysis of Bas1 degradation time course. Cells were 
harvested at multiple time points. The system is extremely sensitive as 
there is no detectable protein by the earliest 20min time point. Bas1 
detection is by anti-flag Ab. 
C. Growth curve functional test of Bas1-AID-flag3 in SDC+NA –ADE 
media with 3 isolates #3857.  
D. Mouse disseminated infection of C. glabrata CFUs (kidney). Limiting 
for glucose control matches the OD of NA starved cells. Only the –NA 
sample leads to hyper-colonization. The Bas1 conditional knockout 
shows a marginal effect and is further confounded by the control empty 





Figure 3.9 IMPD Inhibition. qRT-PCR Induction by MPA and Guanine 
recovery.  
A. Growth curve for BG2-wt #2781 and the affect of the IMPD inhibitor 
Mycophenolic acid at 25 µg/ml (MPA). B. Shows qRT-PCR result of the 
induction ratios of genes after +MPA addition vs. no MPA; cell harvesting 
at hour 9 and 12 growth monitoring. Induction levels are comparable to –
NAD+ levels. C. Growth curve shows that MPA (50 µg/ml) inhibition can 
be overcome by addition of excess guanine (0.3mM and 0.9mM). D. 
Shows the qRT-PCR results of induction ratios where gene expression by 
MPA can be suppressed by addition of guanine almost in a linear fashion 

























































Figure 3.10 IMP-Dehydrogenase Inhibition in Mouse Disseminated 
Infection (UTI).  
C. glabrata cells grown in NAD+ replete conditions (+), NAD+ limiting 
conditions (-), or NAD+ replete + MPA (50 µg/ml) prior to infection. 





















-NA : +NA 
(hst1,sir2)∆ 
-NA : +NA 
TNR1 332 3 
TNR2 245 2 
TNA1 10 0 
EPA6 21 2 
ADE1 6 5 
ADE6 6 3 
ADE4 8 7 
ADE5/7 2 1 
ADE3 2 2 
ADE17 2 2 
ADE8 3 3 
HIS4 20 36 
HIS2 3 3 
HIS7 7 13 
HIS1 7 11 
MTD1 3 2 
SHM2 6 6 
GCV1 2 2 
GCV3 2 2 
SHM1 2 1 
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Table 3.1 (hst1, sir2)∆ Microarray Summary.  
The genes in this table represent the signature set of responders to 
limiting NA conditions. Included are the NA transporter genes recognized 
to be under Hst1, Sir2 regulation (blue highlighted values). The 
remaining sets of genes are confirmed to be up-regulated similar to wild 






Table 3.2 BAS1∆ Microarray Analysis.  
The genes assembled in the table are part of a set of conspicuously up-
regulated members of three biosynthetic pathways (adenine regulon, 
histidine and single carbon THF – tetrahydrofolate). A summary of log 






-NA : +NA 
bas1∆ 
-NA : +NA 
ADE1 1.9 11.0 11.9 2.4 
ADE6 1.9 6.6 4.4 1.9 
ADE4 2.2 4.3 5.5 2.6 
ADE5/7 2.7 5.1 3.9 1.7 
ADE13 1.2 7.0 3.8 1.5 
ADE3 1.6 2.5 2.8 2.6 
ADE17 1.3 2.8 3.2 1.7 
ADE8 1.2 3.9 3.2 1.2 
HIS4 1.9 2.4 6.3 7.4 
HIS2 1.1 1.0 5.6 3.1 
HIS7 1.3 1.3 4.0 4.1 
HIS1 1.1 1.2 3.4 5.5 
MTD1 5.5 8.6 7.0 7.7 
SHM2 1.6 7.5 9.2 2.4 
GCV1 2.1 2.7 5.0 5.9 
GCV3 1.5 2.7 4.0 2.7 
SHM1 1.2 1.7 1.7 1.5 
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microarray experiments. Blue highlighted numbers are notable 





Table 3.3 BAS1-AID-Flag3 Oligo Sequences.  
The BAS1 AID knockout construct was made with multiple fusion PCRs 
and through a combination of site directed cloning and Gibson exo-III 
cloning.  
  
Name  Sequence Enzyme 
bas1 5end 5' agtggatccGAATCTTCGGGATCTACTAGATC BamHI 
3'bas1_flag 
tatcgtcgtcatctttgtaatccttgtcatcgtcgtccttgtagtc
ACTTGGGTTAAGAGGAAGAAA Fusion PCR 
5'flag(12)auxin 
cgatgatgataaaAAAGAAAAGAGTGCTTGCCC
AAAA Fusion PCR 




3'CTA1_NheI gttgagatgagaaaagctagcgct NheI 
bas1 3end 5' 
gtcaagcttAATCTTATTCATTTACTATACTGCT
C HindIII 




cg Fusion PCR 
3'dnAIDflag 
CTCTAGAAAGTATAGGAACTTCTCAtttatcatcatcg





























(Intended to be blank) 
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Chapter 4      Materials and Methods 
4.1 Secondary Structure Prediction and EPA Protein Sequence 
Alignments 
The secondary structure prediction of C. glabrata EPA1 ORF was 
conducted by the open resource PredictProtein (PP; 
https://www.predictprotein.org). The service provides a breadth of 
protein structural annotations including secondary structure features 
such as disulfide bridges, inter-residue contacts, transmembrane helices, 
beta-barrel structures and solvent accessibility. The purpose for the use 
of this tool was to enhance the probability of creating a series of 
structurally stable Epa1 NT fragments encompassing the NT (ATG-K350) 
region as defined by the lectin domain (Rigden, et.al). The usage of 
individual amino acids at the +2 position is one important factor in 
determining protein stability and expression level.  
 
The EPA family of proteins (25) was aligned using the open resource T-
Coffee (http://tcoffee.crg.cat). T-Coffee is a multiple sequence alignment 
server used to create the multiple sequence alignment of Epa proteins to 
the PA-14 domain – more precisely, the experimentally identified Epa 1 
NT lectin binding region (S40 – I283). This homologous region defined the 
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construct boundaries for small-scale mammalian expressions and 
eventual glycan array analysis. Details of constructs found on Table 4.  
4.2 Expression of Epa1 in  E.coli 
Initial heterologous expression and characterization of the recombinant 
ligand binding domains of multiple Epa proteins were focused on 
developing an E. coli system that will allow for efficient production of Epa 
proteins prior to alternative expression systems. I engineered and carried 
out initial characterizations for several recombinant Epa1 N-terminal 
domain constructs using an inducible bacterial expression system for 
purification. Affinity tagged (6xHis) Epa1 was expressed as a fusion to 
sumo (small ubiquitin-like modifier) using a modified pET-28a vector 
(Novagen) retaining most of its features including the Kanamycin marker. 
Pertinent features are detailed in Figure 3. Fourteen fragments 
corresponding to the lectin domain and differing in their precise N- and 
C-termini as described in Table 2 were created as BamHI – XhoI PCR 
products. These were cloned into the modified (His-sumo) pET-28a 
plasmid for expression and purification of fusion constructs. Sequenced 
verified fragments were transformed into BL-21 Rosetta 2(DE3) 
competent cells, for “universal” translation of eukaryotic codons in E. 
coli. Rosetta2 cells use a Chloramphenicol resistant plasmid to express 
rare tRNA genes. Small starter cultures (5ml LB +Cam+Kan) were grown 
at 37ºC and used to inoculate scaled-up cultures at ~ 1:100 dilutions. 
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0.5mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) was used to induce 
Epa expression at an OD600 of 0.6-0.8. Cells were chilled briefly on ice 
(5min) and transferred from 37ºC to an 18ºC incubator shaking at ~225 
rpm and grown overnight. The His-tag along with sumo (Smt3) can be 
removed by Ulp1 (ubiquitin-like protein) specific protease. This step is 
typically carried out directly on the IMAC (immobilized metal-ion affinity 
chromatography) column or post elution followed by a second pass over 
Ni2+. Initial purification was carried out using an IMAC, Ni2+-NTA 
(Qiagen) column or by batch purification. Cells were spun down at 5000 
x g, 5min and pellets were resuspended in 0.5M NaCl, 10mM Tris – pH 
8.0, 3mM CaCl2 and lysed with 10 µg/mL lysozyme. Lysates were 
incubated with Ni2+ agarose resin in batch for at least 1 hour or passed 
over a 10mL resin column by gravity flow for large-scale preparations. 
Bound material was washed with 10 CV (column volumes) 150mM NaCl, 
10mM Tris-8.0, 3mM CaCl2 and eluted in 4-5 CV 250mM Imidazole, 
150mM NaCl, 10mM Tris-8.0, 3mM CaCl2. Samples ultimately run on 
SDS-PAGE for Coomassie stain identification. (Protease Inhibitor Cocktail 
tablets used for lysate buffers were supplied and prepared according to 
(ROCHE) manufacturer instructions. LB Luria-Bertani antibiotic media 
and agar plates used the following working concentrations: KanR 20 
µg/mL, CamR 34 µg/mL).  
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4.3 Cell Culture Maintenance 
Suspension adapted HEK-293 GnTI- cells were originally obtained 
courtesy of Dr. Reeves (MIT, Boston, MA.). The cells lack N-acetyl-
glucosaminyltransferase I (GnTI-) activity, and consequently are unable 
to synthesize complex N-glycans. HEK-293 GnTI- cells were maintained 
in Freestyle media (Invitrogen) and supplemented with 1% FBS, 2mM 
glutamine and 100 µg/ml (penicillin/streptomycin) and passaged at no 
less than 2.0 x 105 cell density. 
4.4 Adapting GnTI- HEK Cells (Dan Leahy) 
Cells were removed from a 95% confluent T25plate by gently banging the 
flask in the presence of 1-3 day old media (5 ml 10% FBS DMEM:F12/ 
Pen/strep). Cells were transferred in old media to a small shaker bottle 
containing 10 ml Freestyle 293 / 1% FBS/added Glutamine 2mM 
final/Pen/strep). Cells should be around 0.2 x 106 per ml at 3 days 
count, split by spinning cells (1000rpm, 5 minute, 4ºC), and resuspend 
cells in fresh Freestyle media (+1% FBS, + glutamine, keep cells under 2 
x106/ml) to about 0.1 to 0.2 X 106/ml. The most important part of 
adapting these cells is to vortex in the fresh media each time you split 
until you see 100% single cells when you are ready to passage again. 
Expect that to be at least 3-5 passages. Once the cells are all single, 
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scale up to larger volumes/cell number. Cells will grow only to 1-2 
million/mL. 
4.5 Mass Spectrometry 
Epa 1 protein samples were prepared for mass spec analysis by the 
Johns Hopkins Mass Spectrometry and Proteomics Facility as detailed by 
the submission protocols. Briefly, protein samples were run on NuPAGE 
Bis-Tris 4-12% gels and stained with Coomassie Blue. Bands were cut 
precisely and pieces were placed in sterile eppendorf tubes. Samples 
were then washed with 50% EtOH and submitted for analysis 
immediately.  
4.6 Expression and Purification of Epa Gene Family  
The Epa1, 6 and 7 N-terminal domains were refined and exactly 
determined by limited proteolysis experiments and mass spec analysis. 
The region (S40-I283) was used as a guiding template for identifying 
homologous domains among all the 25 EPA gene family members. 
Protein sequence alignments were made using the open resource T-
Coffee as described above. Corresponding Epa N-term domain gene 
sequences were PCR amplified from C. glabrata (BG2), and cloned as 
BamHI/XhoI or compatible BglII/SalI fragments into the mammalian 
expression plasmid pαSHS (Cormack-lab, JHU), a modified version of 
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pαSHP-H (adapted from Dan Leahy, JHU, Baltimore, MD.) Constructs 
were expressed as soluble, secreted domains with an amino terminal 
6xHis tag along with a sumo fusion tag. Details of the individual 
sequence constructs can be found in reference Table 4. Purification 
protocols were similarly carried out as detailed earlier in the bacterial 
expression system, with minor modifications. The proteins were made as 
secreted fusion fragments obviating the need for cell lysing. After Ni2+ 
purification, a second affinity-binding step to a lactose-sepharose column 
was performed. Elution fractions from Ni2+ binding were combined and 
passed over a 0.5mL lac-column by gravity flow. The column was washed 
with 20 CV of 150mM NaCl, 10mM Tris-8.0, 3mM CaCl2 and eluted with 
4-5 CV of 200mM β-lactose. Samples were concentrated on Amicon-ultra 
(10K MW) spin down columns at 3500 rpm for ~ 10min. Epa proteins 
were confirmed by Coomassie stain and/or Western analysis. The use of 
LacNac-sepharose (a substrate for Epa1 binding) column was a final step 
used to help determine which family members are stable and potential 
functional lectin binding proteins.  
4.7 Mammalian HEK293 GNTI- Transfection 
Cells were transfected at 1-2 x106 cell density with 100 µg of plasmid 
DNA and 300 µg of PEI (polyethylenimine, Polysciences Inc.), incubated 
for 15 minutes in HSFM (Hybridoma Serum Free Media, Invitrogen) and 
added directly to cells. Several different DNA:PEI ratios were explored, 
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ultimately a 1:2 or 1:3 ratio worked optimally. Recombinant Epa proteins 
were harvested 3 days post transfection from 100ml suspension cultures 
and purified in batch using (Qiagen) Ni2+-NTA resin. Bound material was 
washed 1x with 20 CV (column volumes) of Binding Buffer (BB- 0.5M 
NaCl, 20mM Tris-pH8.0, 1mM CaCl2). Consecutive 20CV washes were 
performed with BB + 20mM Imidazole and BB + 50mM Imidazole. 
Purified protein was eluted with BB + 250mM Imidazole and verified by 
Western blotting with an anti-His antibody (Santa Cruz, SC-2837). 
Subsequently, proteins were promptly dialyzed into 150mM NaCl, 20mM 
Tris-8.0 and 2mM CaCl2 for use directly onto glycan microarrays. 
4.8 Preparation of PEI (Polyethylenimine, Polysciences Inc. 
cat#23966) 
When making DNA complexes, add in DNA in a drop wise manner to PEI 
mixing carefully by pipetting. Mix and leave for 15-20 min before adding 
to cells. Complexes in SFM (serum free media) should be 10% of total 
final volume.  
1. Add 50 mg of PEI to a beaker, adding approximately 40 ml of 
deionized water. 
2. While stirring add 6 N HCl dropwise to the solution until it is ~ pH 
2.0.  
3. Stir the PEI solution until it is dissolved, maintaining the pH at ~ 
2.0 with HCl.  
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4. Add 6 N NaOH dropwise until the solution reaches pH 7.0.  
5. Adjust the final volume to 50ml with deionized water.  
6. Pass the solution through a 0.22-micron filter.  
7. Aliquot to desired volumes using aseptic technique.  
8. Store the aliquots at –20°C or –70°C. 
4.9 Western Analysis 
Protein samples were separated according to their molecular weights 
using sodium dodecyl sulfate denaturing polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by western analysis using standard 
protocols. Briefly, a broad detection range of 4-12% gradient NuPAGE 
Bis-Tris gels (Invitrogen) were used for all protein work. Epa proteins 
were first transferred onto a (Polyvinylidene Fluoride) PVDF membrane 
using Invitrogen’s XCell II™ Blot Module, blocked in 1xPBS - 5% low fat 
dry milk for at least one hour or incubated overnight at 4ºC. 
Subsequently, the primary antibody in 3% milk 1xPBS was incubated for 
at least one hour. The antibodies used were specific for either the poly-
histidine tag (Santa Cruz #8065) or the N terminal of Epa 1 (lab stock 
#3638 rabbit polyclonal), also cross-reactive against Epa6 and Epa7 as 
well. After 1xPBS washes (3x), an HRP linked secondary antibody in 
1xPBS was incubated for at least 30 min. Antibody working dilutions 
were determined empirically but usually 1:5K or 1:10K worked well. After 
a final 1xPBS, wash (3x), the blot was incubated with the substrate from 
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(enzyme linked chemi-luminescence) ECL Plus Western Blotting 
Detection Reagents (GE Healthcare) according to manufacturer protocols. 
The blot was quickly covered in saran-wrap and placed in an 
autoradiography cassette for film exposure.  
4.10 RNA Extraction for qRT-PCR and Microarrays 
The following protocol originally from the Corden lab, was modified by 
Brian Green in our lab. Briefly, yeast cells (20-30 OD units) were 
harvested on 0.45µm filters through a filtration unit and washed with 
4ºC H2O 2x. Cells were then recovered in H2O and placed into 1.5 ml 
screwcap tube. Cells were centrifuged for 30s in a microfuge, the 
supernatant was removed, and the pellet flash frozen in liquid nitrogen 
and stored at -80 C before preparing the RNA. Pellets were placed in 350 
µl AE buffer (0.85 ml 3 M NaOAc pH5.2, 1 ml 0.5M EDTA, 48.15 ml 
DEPC H2O), 50 µl 10% SDS, and 400 µl acid phenol, and incubated at 
65ºC for 1h in Eppendorf shaker at 900 rpm. Every 15 m, the samples 
were vortexed, then on ice for 5m, spun for 5 m in microfuge max speed 
at 4ºC. The aqueous layer was transferred to new tube with 400 µl acid 
phenol and vortexed, then incubated at 65ºC for 5m with shaking and 
vortexed again and back on ice for 5 m. Then, spun for 5m in microfuge 
at max speed at 4ºC. The aqueous layer was placed in new tube with 400 
µl chloroform and vortexed and placed on ice for 5m. Spin again for 5m 
in microfuge at max speed at 4ºC. Aqueous layer was placed in new tube 
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with 40 µl 3M sodium acetate pH5.2 and 1ml 100% ethanol, then placed 
in -80 C freezer for 20m to 1h. Tubes were spun for 15m in microfuge at 
max speed at RT. The supernatant was removed and 1 ml RT 70% 
ethanol made with DEPC H20 was added. Spin again for 5m in microfuge 
at max speed at RT then pour off supernatant, quick spin, and aspirate 
liquid completely with pipette. Let tube sit open for 10 m on ice to dry 
pellet. We usually continue with a DNAse step in DEPC H2O and another 
phenol: chloroform extraction and 70% ethanol wash. RNA is then 
diluted 1:50 and run on an agarose gel for quality control. 
4.11 Glycan Microarrays Analysis 
Glycan array analysis was performed by the Consortium for Functional 
Glycomics; protocol CFG#2556 (http://www.functionalglycomics.org). 
Lectin proteins were isolated and purified as described earlier by a two-
step protocol (Ni2+ and Lac-sepharose) followed by fluorescent labeling. 
The proteins were conjugated with the Alexa-Fluor 488 dye for detection. 
Resulting data was sorted and tallied in Excel into major catalogue 
groups; linkage type, terminal sugar, hydroxyl C-positions, penultimate 
sugars and glycan modifications to generate relative binding figures for 
each lectin tested. 
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4.12 DNA Microarrays In-house 
For each sample, total RNA was prepared (as described above) by warm 
acid phenol extractions and cDNA was made by first strand synthesis 
(SuperScript II, Invitrogen#11904018) or homemade RT. Visual 
inspection of the 28S and 18S rRNAs on agarose gels was used to ensure 
quality of RNA isolation. Total RNA was DNAse treated and resuspended 
in DEPC-H2O before cDNA production. Finally, RNA was 
spectroscopically quantified at 260 nm. The integrity of RNA was verified 
by an optical density (OD) absorption ratio OD260/OD280 between 1.8 and 
2.0. The following is a brief overview of the array setup; a Li lab protocol 
modified by Brian Green in our lab. Cy3 or Cy5 conjugated cDNA was 
prepared for each sample using anchor dT primers and a 3mM aa-
dUTP/dNTP mix (4:1 aa-dUTP:dTTP). Differentially labeled experimental 
and control cDNA preparations were pooled, heated to 100°C for 2 min, 
and hybridized overnight at 63°C in 3xSSC, 25mM HEPES pH7.0, 0.25% 
SDS on in-house oligonucleotide microarrays. Arrays were washed 3x by 
vigorous plunging in 2xSSC, 0.2% SDS at 60°C, rinsed 1x in 0.1x SSC, 
spun dry and scanned with a GenePix 4000B (Axon Instruments). Spots 
were found and analyzed with GenePix Pro 3.0 analysis software. Image 
data files of the GenePix Results (GPR) were imported into the Acuity 
database for analysis. Ratio-based normalization of arrays is the method 
implemented by GenePix Pro. Log ratios have the advantage of being 
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normally distributed and can easily reveal properties of the data. The 
software also applied filters for background and spot similarities so that 
low intensity spots at or near background levels and spots that differed 
more than twofold in their expression ratio were eliminated. We note 
specifically that we did not obtain sufficient reproducible replicates to 
properly analyze our data through SAM (significance of analysis of 
microarrays) software. Our tables were generated by hand for a number 
of chosen genes whose values were averaged after log2 transformations. 
4.13 Quantitative RT-PCR 
A number of strains were used for these studies: 
 
The strains were grown in SDC (synthetic complete amino acids) and 
excess NA at 30ºC overnight to log phase (OD600 ~0.5), washed in PBS 2x 
and placed in fresh media at OD600 ~ 0.05 with replete (3.25 µM NA) or in 
the absence of NA. Cells were recovered at log phase or during stationary 
phase according to experimental design. RNA was extracted as described 
Strain # Gene 










above except our first strand synthesis is done with homemade RT. 1 µl 
of cDNA was used as the template in real time PCR reactions with primer 
pairs for TNR1, TNA1, MTD1, SHM2, HIS4, ADE1, ADE3, ADE4, EPA6 and 
HHT2. Real time PCR was performed on Bio-Rad C1000 Thermal Cycler 
in 96-well plates. Real-time PCR efficiencies were acquired by serial 
dilutions of 10ng µl-1 of genomic C. glabrata DNA to generate standard 
curves for each gene. RNA equivalents were normalized to HHT2 
transcript levels. qRT-PCRs were done in duplicate wells from each of at 
least three independent biological samples for experiments that display 
error bars. A master-mix (20 µl well-1) of the following reaction 
components was prepared: 8.25 µl of water, 2.5 µl of 10x PCR buffer, 
2.5 µl of Primer mix (or 1.25 µl of Forward, 1.25 µl of Reverse), 2.5 µl of 
10mM MgCl2, 2.5 µl of dNTP mix (2 mM each), 0.25 µl of Taq polymerase, 
1.25 µl of EvaGreen 20x stock (Molecular Probes, Eugene, Oregon), 
aliquoted into each of the wells on the 96-well PCR plate. 5 µl cDNA per 
well was used; from 1:20 dilution. The following general real-time PCR 
protocol was used: Heat activation of polymerase (in house-Taq) for 2 min 
at 95°C, 40 cycles of PCR: 95°C for 10 s, 65°C for 20 s, 72°C for 20s. 
Melting curve analysis was carried out to confirm the specificity of the 
amplicons. Quantification of gene expression differences was performed 
using the ‘delta-delta-CT’ method with HHT2 as the normalizer gene. 
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4.14 Animal Studies 
Nine-week old Balb/c female mice (Taconic) were typically used in our 
limiting NA (nicotinic acid) experiments.  Prior to tail vein injections C. 
glabrata strains were grown at 30ºC in SDC (synthetic complete + 2% 
dextrose). When cells reached mid-log phase (OD: 0.55) they were diluted 
back and shifted to SDC media in the presence of NA 3.25 µM or absence 
of NA and grown to stationary phase. Cells were collected by 
centrifugation and washed 2x in ice cold PBS and resuspended at a 
concentration of 1 x 107 cells ml-1. Numbers of cells were determined by 
spectrophotometry OD600. Mice were injected with ~1 x 107 cells in PBS 
via tail vein injections in a total volume of 0.1ml. Each yeast strain used 
a group of 7 to 10 mice per experiment. Mice were sacrificed and target 
organs were harvested seven days post-infection. Tissue homogenates 
were plated on YPD plates supplemented with Pen/Strep (Penicillin 100U 
ml-1, Streptomycin 100 µg ml-1). Viability and counts were confirmed by 
assessing cfu from appropriate dilutions on YPD Pen/Strep plates, 
incubated for 24 -48 hrs at 30ºC. CFUs for all samples were tallied and 
the geometric means for all groups were determined.  
4.15 Cloning of Bas1 – Auxin Inducible Degron (AID) 
The AID system was generated in a series of steps with multiple fusion 
PCRs into the pOZ16 URA+ plasmid. The yeast strain #3857 was created 
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by integration of the BAS1- FLAG3-AID-FLAG3 construct with a URA+ 
marker and a hygromycin selection cassette into the parental strain 
BG14 URA= (#430), done by a two-step method. The hygR marker would 
be removed by transformation with pRD16 FLP (flippase). Schematically, 
the auxin inducible degron (AID) tag was subcloned from the Auxin 
plasmid BYP7430 and placed immediately 3’ of the BAS1 ORF. This was 
followed by 3x-Flag tag and a stop codon. BAS1 500bp fragments 
corresponding to the terminal ORF region and the 3’ UTR genomic region 
immediately past the stop sequence were PCR amplified and cloned into 
pOZ16 as BamHI – NheI and HindIII – SalI fragments respectively. The 
BamHI fragment was made with two fusion PCRs consisting of Fusion I 
(flag-AID  700bp and 3’CTA1 200bp) product. Fusion II was made with 
BAS1-flag 500bp and the Fusion I product. The construct is now BAS1-
flag-AID in pOZ16. A Flag tag (3x D-Y-K-D-D-D-D-K) was incorporated 
into the appropriate oligos following BAS1 and AID. The second flag tag 
was made as a fusion PCR consisting of the BAS1-flag-AID-flag (1.2kb) 
and flag-CTA1 (250bp) products. The overlapping flag sequence is 
denoted in bold. The BAS1 HindIII – SalI fragment was placed 3’ of the 
FRT site downstream of the HygR marker. The TIR1 component was 
introduced into pGrb2.3 (B2039) at XbaI – XhoI sites as a Gibson cloning 
PCR product (New England Biolabs #E5510S).  
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A noteworthy caveat: when generating AID tagged proteins, never place 
the AID degron exposed at the C-terminal end as this will result in 
immediate degradation of your desired protein.  
4.16 Gene Deletions in C. glabrata   
Gene deletion in C. glabrata was done by a one-step method. The ORF of 
the gene was either replaced with a nourseothricin (NAT) cassette or 
completely deleted. The sequence information was obtained from the 
Genolevures website as well as our own in-house sequencing database of 
the BG2 strain. The genes BAS1, BAS2, (BAS1,2) and GCN4 were deleted 
in this manner. For deletion with NAT cassette, the 5' and 3' 
untranslated regions of each gene to be deleted, as well as NAT cassette 
were PCR amplified. The three PCR fragments were then used as 
templates for fusion PCR where the three pieces were joined into one. 
The fusion PCR product was purified with the Qiagen gel purification kit 
then transformed into C. glabrata via the lithium acetate method and 
selected on YPD plates supplemented with 200 µg ml-1 NAT. Homologous 
recombination and allele replacement of each locus was verified by PCR 
analysis using a primer that anneals in the sequences external to the 
cloned fragments and a primer annealing within the NAT cassette. We 
also verified the absence of a gene by inability to PCR amplify an internal 
fragment from each deleted gene. 
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4.17 Strains and Media 
Yeast cells were grown on standard yeast media YPD or synthetic 
complete (SC-Hopkins) supplemented with 2% dextrose. When necessary 
SDC media was supplemented with Adenine 25 µg/ml or Tryptophan 85 
µg/ml. All Candida glabrata deletion strains were derived from our wild 
type lab strain BG2 or from an ura3 derivative of BG2, BG14. All bacteria 
were grown in LB medium supplemented with 100 µg ml-1 carbenicillin at 
37°C. For plates LB + agar was added. When needed plates were also 




Chapter 5      Conclusion        
      These two major projects were aimed at understanding the virulent 
pathways of the yeast pathogen C. glabrata. In the first study we 
addressed a structural biology question by creating a unique system to 
generate a functional protein of a critical Epa domain known to be 
responsible for the binding of yeast cells to human host epithelial cells. 
Understanding the essence of the binding interface in the first step of 
pathogenesis is essential toward developing new therapies against fungal 
infections. Additionally, a series of glycan microarrays experiments led to 
further support and characterize the ligand binding specificities of a 
family of lectin adhesion proteins known as epithelial adhesins (EPA) to 
host glycan moieties. The second study focused on delineating the 
regulatory pathways that are activated during exposure to an NA limiting 
environment that lead to a hyper-colonization phenotype.  
 
      For the first project, we fell short of solving the X-ray crystallographic 
structure of the Epa1 although those efforts were refocused toward the 
entire family of adhesins that yielded a wealth of glycan binding 
information for six different EPA adhesins. It was an effort that entailed 
the creation of 25 different expression constructs and generated a series 
of Epa ligand binding domains for functional testing. For Epa1, 6 and 7 
our data were consistent with the importance of key cysteine residues for 
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the functional architecture of the PA-14 domain within the N-terminal 
region. This idea was borne out in the published structure of the Epa1p. 
Additionally, our work showed that for a number of these lectins (Epas 
12, 23, and 25), they exclusively prefer binding to sulfated glycan 
residues. Sulfated residues are found in a number of different tissues 
and are a preferred strategy for gaining access and colony establishment 
for many other disease causing microorganisms. The high degree of 
binding specificity of the EPA proteins for varying types of cell surface 
glycans present a tempting opportunity for utilizing these proteins as 
non-invasive diagnostic strategies for detecting aberrant glycosylation 
underlying various disease states.  
 
      The second major study addressed the hyper-colonization phenotype 
observed during a mouse model of disseminated infection of C. glabrata. 
This virulence program is characterized by the up regulation of a set of 
genes that control three distinct pathways: purine and histidine 
biosynthesis and 1-Carbon metabolism.  By making use of a series of 
deletion mutants in genes orthologous to the S. cerevisiae BAS1 and 
BAS2 genes, genes known to be involved in the regulation of these 
central metabolic pathways in S. cerevisiae, we could show that Bas1 is 
required for induction of these metabolic pathways in response to a low 
nicotinic acid (NA) signal. A low niacin environment is the critical inducer 
of the pathogenic state. Analysis of these mutants through microarrays 
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and qPCR experiments alerted to the presence of additional factors 
necessary for complete induction or complementary to the bas1 
knockout, and GCN4, a regulator of amino acid biosynthesis genes in S. 
cerevisiae was also uncovered as an indirect participant in the activation 
of several genes in purine biosynthesis independent of Bas1p. It was 
discovered that although GCN4 is not required for the hyper-colonization 
phenotype, it did in fact have a synergistic affect with BAS1 resulting in a 
complete failure of gene expression when yeast cells were exposed to 
limiting NA conditions. Direct cooperative association between Bas1p and 
Gcn4p remains to be established.  
 
      Why were these three pathways so strongly up regulated? Additional 
sets of experiments attempted to answer that question and tested the 
downstream affects of the absence of NA as an enzymatic cofactor that 
directly impacts the generation of GMP/GTP. We hypothesize that the 
absence of NA leads to an inhibition of IMP to GMP conversion. In 
support of this hypothesis, we were able to mimic the limiting NA 
phenotype in our mouse infection experiments via inhibition of IMP-
dehydrogenase with mycophenolic acid, an inhibitor of IMPDH. These 
results helped take another step forward in identifying how limiting NA 
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